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ABSTRACT  
   
The living world we inhabit and observe is extraordinarily complex. 
From the perspective of a person analyzing data about the living world, 
complexity is most commonly encountered in two forms: 1) in the sheer 
size of the datasets that must be analyzed and the physical number of 
mathematical computations necessary to obtain an answer and 2) in the 
underlying structure of the data, which does not conform to classical 
normal theory statistical assumptions and includes clustering and 
unobserved latent constructs. Until recently, the methods and tools 
necessary to effectively address the complexity of biomedical data were 
not ordinarily available. The utility of four methods--High Performance 
Computing, Monte Carlo Simulations, Multi-Level Modeling and Structural 
Equation Modeling—designed to help make sense of complex biomedical 
data are presented here. 
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CHAPTER 1 
INTRODUCTION 
Introduction: 
Berman defined biomedical informatics as, “the branch of medicine 
that combines biology and computer science” (Berman 2007). Musen & 
Van Bemmel suggested that the pervasive cognition that computers are 
the predominant focus has contributed to a “tendency to define any 
activities with heavy computer focuses as informatics” (Musen and Van 
Bemmel 2004). For years there was a strong push to see computers in 
biomedicine as a predominant focus in biomedical informatics (Shortliffe 
and Cimino 2006). 
While computers are highly useful tools, they are not solutions to 
biomedical problems in and of themselves. Having large well curated 
collections of information that can be easily exchanged and shared is 
useful only insofar as we can analyze the data and make sense of what it 
means. Absent the ability to effectively analyze biomedical data, the 
potential for making advancements in medicine is unrealized. We need to 
be able to decode an understand what the vast amounts of biomedical 
data mean in order to develop new diagnostic screening tools for disease, 
clinical decision support systems or guidelines for addressing specific 
public health problems.  
Despite the ever growing need to analyze biomedical data, the task 
is especially challenging in biomedicine because of the size and 
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complexity of the data. Cios and Moore specifically discuss the 
uniqueness of biomedical data compared to other fields and note that 
“researchers in other fields may not be aware of the particular constraints 
and difficulties of the privacy-sensitive, heterogeneous, but voluminous 
data of medicine” (Cios and Moore 2002). Additionally, Cios and Moore 
also note that the “mathematical understanding of estimation and 
hypothesis formation in medical data may be fundamentally different than 
those from other data” (Cios and Moore 2002). National Institute of 
Heath’s Common Fund which is part of the Division of Program 
Coordination, Planning and Strategic Initiatives (DPCPSI) suggests that 
while there are many new challenges in dealing with biomedical data that 
“at the core of the challenge [today] is one of “big data” where handling 
and working with complex data at a large scale is both quantitatively and 
qualitatively different than at a smaller scale” (NIH 2011).  
As a result, there is a need to develop, adapt and disseminate 
methods to help address challenges and complexity inherent in modern 
biomedical data. In this dissertation, four methods, High Performance 
Computing, Monte Carlo Simulations, Multi-Level Modeling and Structural 
Equation Modeling that help address challenges posed by complexity in 
biomedical data are described in the context of their application to specific 
real-life problems. 
Origins and Nature of Complexity: 
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Complexity in modern biomedicine is a product of 1) millions of 
years of complex evolutionary change and 2) advancements in technology 
which enable the generation and storage of massive quantities of data 
(Crick 1988). (Cios and Moore 2002) (NIH 2011).  
The notion that biomedical data has become increasingly complex 
has become a major theme among premier scientists in the past few 
decades. Dr. Francis Crick, a co-discovered the double helix structure of 
DNA and among the most influential scientists of the 20th century, was one 
of the first to articulate this theme. The preface for his 1988 book, “What 
Mad Pursuit” specifically states that “science in [the 20th] century has 
become a complex endeavor” (Crick 1988). In the book, Dr. Crick expands 
further on the notion of biomedical research being complex with the 
recurrent argument that, “while Occam's razor is a useful tool in the 
physical sciences, it can be a very dangerous implement in biology. It is 
thus very rash to use simplicity and elegance as a guide in biological 
research” (Crick 1988). Dr. Crick suggests that part of the reason for the 
inherent complexity in the biological sciences and its lack of grand 
theories is a product of evolution. While biologists have ‘laws’ such as 
Mendelian inheritance, these are not nearly as precise or accurate as, for 
example, the theory of relativity. In physics, the laws were set from the 
start and are not the product of incremental change over time. In biology, 
what we observe is the product of millions of years of sequential 
evolutionary changes with each change or adaptation built upon the 
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previous (Crick 1988). Dr. Crick urges us to consider that while the end 
product is not always the most efficient system possible, nature had to 
build sequentially on what was already there to obtain the complex end 
result we see today.  
Numerous noteworthy scientists have directly commented positively 
on Dr. Crick’s views. For example, Phillip Anderson, who won the 1977 
Nobel Prize in physics for his work on the electronic structure of magnetic 
and disordered systems which paved the way for many modern computing 
systems, specifically said that as a general principle for “learning the truth 
about the world around us, Crick’s words are as good a guide to that end 
as I have seen” (Anderson 1990). 
 Adding to the inherent complexity of the natural world that Dr. Crick 
and others discuss are the explosion in the physical amount of data about 
the natural world and its structure that is spurred on by advances in 
computers and technology (Cios and Moore 2002) (Chen, et al. 2010) 
(Shortliffe and Cimino 2006). For example, the microarray is a relatively 
new technology used to measure genomic and proteomic properties of an 
organism which has massively increased the size of data. It is common for 
current generation microarrays to have tens of thousands to over a million 
data points on each array or for each subject or individual organism 
present in the study design (Brown, et al. 2011) (Affymetrix 2012). 
Secondly, database systems, information transfer technologies and the 
availability of inexpensive storage solutions are some factors which have 
  5 
contributed to an increasing number of dedicated data repositories which 
collect, integrate and when agreed upon share data or results. A few 
examples includes the Center for Health Information and Research which 
contains information on millions of patients and tens thousands of doctors 
in Arizona or the National Cancer Institute’s Cancer Biomedical 
Informatics Grid known as caBIG which collects and shares data from 
over 700 cancer research institutions (Johnson, et al. 2011) (Nationanl 
Cancer Institute 2012). The massive quantity of data produces a 
significant computational challenge to be able to efficiently analyze the 
data.  
Large datasets, including those from microarray experiments and 
data repositories can lead to further complexities in the data such as the 
presence of multi-level structures. Also, many modern statistical methods 
are iterative and take many cycles to complete which compound the 
computational burden associated with voluminous amount of data. 
(Muthen and Muthen 2011).  
Overview of Methods: 
The dissertation is divided into four chapters: high performance 
computing methods, Monte Carlo Simulations, multi-level modeling and 
finally structural equation modeling. The first two chapters describe near 
universal methods which help facilitate any quantitative analysis in 
biomedicine. The third chapter serves as a transition and shows that 
newer and more complex modeling approaches are necessary to obtain 
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accurate results; such as when clustering and multi-level structures exists 
in the data. In addition, the multi-level modeling chapter also shows that 
newer modeling approaches to address complexity in biomedical data also 
allow researchers the ability to investigate relationships not possible with 
simpler models. The fourth chapter on structural equation modeling 
extends the notion that newer methods are often necessary to fully 
understand complex data and shows how structural equation modeling 
allows researchers new opportunities to develop diagnostic tests and to 
model unobservable latent constructs.  
High Performance Computing Overview: 
The high performance computing chapter lays out a number of 
methods and tools which are highly and nearly universally applicable to 
address problems of large data in biomedicine. The high performance 
computing methods presented in chapter 2 help address the informatics 
challenges of managing large data as well as physically running the large 
number of computations that are often necessary in an efficient fashion. 
This chapter details the use and benefits of database connectivity, pipeline 
parallelism, multi-core processing and distributed multi-core grid 
processing. This chapter is not meant to be an exhaustive treatise on 
computer science solutions to big data problems. Not only does the 
chapter not address every computer science challenge to big data, the 
scope in which they are examined is tailored towards individuals 
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performing quantitative analysis of biomedical data. The topics presented 
were also used to facilitate the utilization of the other 3 method chapters. 
Secondly, much of the literature on topics such as parallel 
processing is not tailored towards analysts and much of the relevant 
information is scattered throughout a number of different sources (ie. SAS 
manuals for example). The goal here is to present a number of tools, 
explain their utility and provide scripts and examples to help facilitate their 
implementation. The concrete examples and scripts that are included are 
focused at quantitative analysts and designed to make using such 
methods easier for many analysts.   
Monte Carlo Simulations Overview:  
This chapter advocates for broader use of Monte Carlo simulations 
in order to assess whether the models being used give accurate results as 
well as to pick the best alternative when one model fails.  Many statistical 
assumptions such as homogeneity of variance (equal variances between 
two groups (Cohen, et al. 2002) (Keppel and Wickens 2007)) are 
commonly, and sometimes by design, egregiously violated in biomedical 
data (Quackenbush, Causton and Brazma 2003). It is impossible to make 
sense of biomedical data and to make scientific advances if the statistical 
models a researcher is using do not giving accurate answers. The 
problem of inaccurate models is exacerbated by big data.  A Monte Carlo 
simulation is a method for testing mathematical models in which a large 
number of datasets are randomly generated to mimic a given set of 
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properties. A model is then tested on each random dataset and the results 
are recorded to gain insight into model behavior. Given the complex 
nature of biomedical data, Monte Carlo Simulations are an indispensable 
method to help confirm that on average over repeated sampling the 
results obtained from an analysis are accurate.    
Although Monte Carlo simulations have been a defacto standard for 
validating new statistical models for decades, the computational demands 
have largely kept them from being more widely used in routine statistical 
analyses (Fan 2002). Since many modern methods such as maximum 
likelihood are iterative there is no analytic solution to derive and 
simulations are the only way to determine model performance (Fan 2002) 
(Rubinstein and Kroese 2007). While it is advocated for a wider more 
general use of Monte Carlo simulations, even in smaller biomedical data 
sets when assumptions are not met, the even larger challenge today is 
comes from big data. Given the size of many modern biomedical datasets 
the question is not just restricted to which method will perform well under 
one specific set of conditions (ie. one pairwise contrast), but rather which 
will perform best over multiple comparisons across the entire range of 
data. With modern microarrays or databases containing population health 
information where tens of thousands or millions of observations are 
available, there may likely be a large spread in variances or adherence to 
model assumptions across the range of statistical contrasts. As a result, 
the question with big data becomes not which model is most accurate for 
  9 
any single contrast but which model is most accurate across the entire 
surface and range of responses in the data that will be taken into account.  
One major challenge with big data is physically running the tens of 
thousands or millions of statistical tests so advocating running equality of 
variance tests on every observation is not realistic; even with the HPC 
methods that are presented in chapter 2 to help. Rather, sampling 
methodologies are suggested as an alternative. Depending on the 
structure of the experimental design, simple random sampling, stratified 
random samples, cluster randomized or even a multi-stage probability 
sample of a small portion of the data can be drawn. From this smaller and 
manageable subsample, screening tests on the data can be run and a 
Monte Carlo simulation can be created to determine the best method 
given the structure and surface of the dataset.  
While sampling methodology helps reduce computational demands, 
HPC implementations for Monte Carlo simulations are presented to help 
make Monte Carlo simulations themselves possible as a part of general 
research routine and process flow. Single core and parallel processing 
SAS macro programs and templates are provided to help users more 
easily perform Monte Carlo simulations. 
Multi-Level Modeling Overview: 
This chapter demonstrates the proper use of Multi-Level modeling 
to address the complex problem of clustering in biomedical data with the 
real world example of modeling adherence to treatment. In addition to 
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general correction for clustering, the chapter also illustrates the effective 
use of centering and how variance components estimated at the unit of 
observation and at the unit of clustering can be analyzed to help unravel 
the complexity in biomedical data. 
Unlike violations of homogeneity of variance discussed extensively 
in the Monte Carlo simulation chapter, it is well understood and agreed 
that multi-level modeling is the correct approach to take to deal with 
violations of independence of observations. (Raudenbush and Bryk 2001) 
(Cohen, et al. 2002) (Tabachnick and Fidell 2006). The assumption of 
independence assumes that each observation is uncorrelated with or 
independent of every other observation in the dataset. The primary way in 
which this assumption is violated is when clusters or nesting exist within 
the dataset. This sort of clustering or nesting is pervasive in modern 
biomedical datasets; especially those derived from databanks. A few of 
the more commonly encountered biomedical clustering problems are: 
doctors are nested within hospitals, patients are nested within doctors, 
tissue samples might be nested within lab if a research group obtains 
samples from multiple tissue banks or repeated measures within the same 
patient such as blood tests over the course of time. Even very small 
violations of independence can lead to dramatically inflated type 1 error 
rates (Raudenbush and Bryk 2001). 
Stulberg et al. 2010 used a multi-level model to control for 
clustering created by taking measurements across multiple hospitals and 
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Mills et al. 2006 used multi-level modeling to account for regional 
clustering in the sampling design across geographic regions (Stulberg, 
Delaney, et al. 2010) (Mills, et al. 2006). Wile there are numerous 
examples of multi-level modeling being used in premier journals such as 
JAMA, there are also examples in which no metion of efforts taken to 
control for possible clustering. Parker et al. 2009 propose a possible gene 
signature for breast cancer samples but they use samples from two 
distinct sample types fresh frozen and parrifin fixed formalin embedded 
(FFPE) which come from 5 different cohorts (Parker, et al. 2009). Across 
the many different comparisons performed, there is no mention of 
clustering in the paper. While the probablity does exist that the effect was 
neglegible, this is highly unlikely. Personal research not discussed in detail 
in this dissertation found that with similar breast cancer samples from 
multiple cohorts exhibited intraclass correlations (a measure of clusering) 
in excess of 0.6 (Seliegman and Brown 2011).  
Additionally, although multi-level modeling is sometime used when 
necessary, many papers in biomedicine such as Stulberg, Delaney, et al. 
2010 or Mills, et al. 2006 are uninterpretable because they omit key 
information about the model estimation and specification such as how the 
variables were centered. This is because the complex relationship 
between an independent predictor and dependent variable is comprised of 
variability at the unit level of observation as well as at the cluster or 
grouping level. Variability can be partitioned in different ways based on the 
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research question of interest. The researchers decisoin on how to partition 
variance determines the interpreatation of the paramter estimates 
(Raudenbush and Bryk 2001) (Enders and Tofigi 2007). Without knowing 
critical model specifications such as centering, it is impossible to 
accurately interpret the paramete estimates and to know if the model 
estimated is confounded (Raudenbush and Bryk 2001) (Enders and Tofigi 
2007).  
While using multi-level modeling to correct for clustering is a useful 
and necessary procedure, multi-level modeling provides a plethora of 
additional information beyond simply correcting for the structure in the 
data which does not meet certain statistical assumptions. Most authors in 
biomedicine, Stulberg and Mills included do not make use of the additional 
information and estimates provided generated when running a multi-level 
modeling. The extra complexity of multiple levels of clustering also 
provides additional sources of information and is something that helps us 
better unravel complexity. In multi-level modeling the equations and 
variance components are estimated separately for each level of a given 
cluster. One example of the utility of this which is presented later is that 
this approach allows us to estimate the relative amount of variability in 
adherence to medical treatment for doctors and patients separately. Multi-
level modeling is generally underutilized in biomedicine and when it is, it is 
almost exclusively used to correct for clustering rather than using the 
additional complexity to help better explain the world around us. 
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Structural Equation Modeling Overview: 
The final chapter focuses on structural equation modeling in 
biomedicine. The modeling approach described here addresses another 
situation where simpler modeling approaches do not fully capture the 
richness of the data and complexity of the natural world. Multi-level 
modeling is a mathematical subset of structural equation modeling. The 
origins of structural equation modeling date back to path analysis in the 
1920’s. Innovations in computer processing combined with the 
development of algorithms, such as estimation maximization (EM), that 
help efficiently perform maximum likelihood estimation have led to an 
increased popularity of structural equation modeling in many areas of 
research especially in the social sciences. Structural equation modeling is, 
however, relatively underutilized in biomedicine.  
In the few cases where structural equation modeling is used, the 
authors often specifically advocate for wider use of the method (Dahly, 
Adair and Bollen 2009). Tu 2009 argues more generally for expanded use 
of structural equation modeling as a potentially highly useful tool for 
advancing epidemiology and biomedicine (Tu 2009).  
One aspect of structural equation modeling which is especially 
useful in biomedicine is latent variable modeling. Often times the specific 
objects or theory of interest are measured indirectly. For example, peptide 
microarrays use random 20mer peptides to indirectly measure the 
presence and activity of antibodies in a sera sample when a part of the 
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antibody binds to one or more of the peptides on the array. Simple analytic 
methods such as a t-test, analysis of variance or logistic regression can 
determine if there are differences in expression of a peptide between 
groups but cannot tell us anything about the entire antibody of interest. 
Structural equation modeling provides a framework to not only infer which 
peptides might represent binding of a single antibody, but also provide 
detailed information about the latent antibody itself; such as how the 
antibody might correlate with disease status. This chapter describes latent 
class modeling of peptide data.  Additionally, it demonstrates how latent 
class modeling can be useful as a medical diagnostic algorithm. 
Discussion: 
In summary, millions of years of sequential evolutionary pressure 
and random variation, each building upon the last, has helped to create 
the complex living world we inhabit and observe today (Crick 1988). 
Additionally, modern technological advances, primarily via computers, 
have created many additional complex challenges stemming from big 
data. Four methods, high performance computing, Monte Carlo 
simulations, multi-level modeling and structural equation modeling are 
presented to help address challenges posed by complex modern 
biomedical data. Furthermore, while simpler analytic methods can be a 
good starting points, there are many occasions in which more complex 
modeling techniques are necessary to obtain accurate results. The more 
complex models explored estimate new parameters and allow researchers 
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to investigate relationships between variables and better unravel the 
complexity in modern biomedical data in ways not possible with more 
simplistic models. The hope is that the methods demonstrated in this 
dissertation will help accelerate the pace of biomedical discoveries; which 
will in the end help to ameliorate the quality of life for countless individuals.   
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CHAPTER 2 
HIGH PERFORMANCE COMPUTING METHODS IN SAS 
Chapter Overview: 
 This chapter presents four high performance computing methods: 
database connectivity, pipeline parallelism, multi-core parallel processing 
and distributed grid parallel processing. These methods are presented to 
help analysts cope with 1) the voluminous nature in physical size of 
modern biomedical datasets and 2) the computational increases 
associated with iterative algorithms which are common in many modern 
statistical models. Program code and example syntax is provided in SAS 
because it is the most widely used statistical analysis program in the 
world. Analytic results are presented that demonstrate the dramatic 
decrease in computational time from using these methods.   
Problem Abstract:  
Modern technological advancements such as microarrays and 
database technology have led to an explosion in the amount of data that 
must be or is available for analysis. This explosion of data has made it 
difficult to physically do all of the computations necessary to process large 
datasets or to run interactive models in a reasonable time frame. A 
number of computer science methods exist to help deal with the physical 
processing constraints. Unfortunately, many of these methods, such as 
parallel processing and distributed grid computing, require highly 
specialized computer science skillsets which many average analysts lack. 
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The goal of this chapter is to provide a set of templates and tools that 
allow average analysts the ability to easily and more efficiently make use 
of high performance computing methods. The use of database 
connectivity, pipeline parallelism, multi-core parallel processing, and 
distributed grid computing are described as tools to help process the large 
quantities of data in modern biomedical datasets.  It is shown how using 
such methods reduce dramatically the storage needs and the time needed 
to analyze complex and voluminous biomedical data.  
The methods are demonstrated using SAS. SAS was chosen 
because it is the world leader in analytic software. SAS analytic software 
is used by more than 55,000 sites including businesses, governments and 
universities in 129 countries. Additionally more than 90% of the Fortune 
Global 500 companies use SAS (SAS Institute 2012). Presenting these 
methods in SAS provides a common language and platform through which 
many analysts are already familiar; thus making the methods accessible to 
as large a group of analysts as possible.  
Background: 
The use of relational databases to store data has been well 
documented (Elmasri and Navathe 2006). Some of the reasons for storing 
data in relational databases are: improved retrieval of information, 
elimination of redundancy and reduction in storage space needs, and the 
potential for integrating multiple forms of data quickly and easily. Many 
text books such as those published by Elmasri & Navathe and Shortliffe & 
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Cimino specifically discuss these benefits of storing biomedical data 
(including genomic data) in databases (Elmasri and Navathe 2006) 
(Shortliffe and Cimino 2006). Beyond the many general discussions of the 
benefits and general strategies, authors such as Corwin, Siliberschatz, 
Miller & Marenco propose very specific database solutions such as the 
use of dynamic tables for storing biomedical data in relational databases 
(Corwin, et al. 2007).  
The one thing that is usually missing from the discussion of 
relational databases in biomedicine is commentary on integrating 
databases with analytic software such as SAS. Having large well curated 
databases that are optimally normalized, can be easily exchanged and 
shared seamlessly across platforms is useful only insofar as the data can 
be analyzed and interpreted. An external program is almost always used 
to analyze the data and if a researcher cannot easily integrate the data 
with a database, many of the efficiencies and gains from a database are 
lost. Database connectivity is a fairly simple technology implemented in 
many programs such as SAS, SPSS, MATLAB and others. Connecting an 
analytic program directly to a database speeds up the process by not 
requiring the output of a flat file (such as a .csv or excel file) to the be 
loaded into an analytic program, reduces potential errors in exporting and 
importing as well as reducing storage size on disk necessary for 
replicating database information in flat files. Unfortunately, the benefits 
and process of database connectivity is not always explained in a 
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straightforward way to end analytic users (Shamlin 2009) (Stokes, 
Bradstreet and Hill 2002). 
Another highly useful tool is parallel processing and distributed grid 
processing. There has been a large focus in the biomedical literature on 
high performance computing (HPC) focuses on supercomputing clusters. 
In addition to technical papers, companies such as Cray and IBM 
extensively market to the biomedical community while many research 
institutions such as Arizona State University offer training on how to use 
HPC environments. Unfortunately HPC clusters are not available to many 
researchers or institutions and programming in an HPC environment 
requires an additional highly specialized skill set (Hager and Wellein 
2010). While many analytic programs offer some level of parallelization, 
this dissertation specifically focuses on SAS.  
Part of the reason for focusing on SAS or an analytic package 
generally is because the complex mathematical operators of modern 
statistical methods are already implemented. While one could theoretically 
program his or her own maximum likelihood and estimation maximization 
algorithm to perform structural equation models in a language 
understandable to a HPC system, the difficulty and time necessary to do 
so would be quite high. SAS offers a number of modules to help 
implement parallel processing in an easy and efficient fashion. Integrating 
them into a workflow can dramatically reduce the time needed to perform 
computationally intensive analyses.  
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Modern analytic packages such as SAS have become so large that 
even individuals who have used such programs for years are unaware of 
many of the HPC related features which have shown up in recent years. In 
addition, even when many researchers are aware they exist, some do not 
immediately recognize the benefits they provide to the biomedical 
community and many often assume that they are so complex that their 
use will be difficult. Most of the literature on the application and use of 
HPC parts of SAS are contained in their technical manuals and SAS User 
Group International (SUGI) publications.  
The technical manuals are complex to understand and not well 
organized. HPC applications are spread across multiple different SAS 
applications requiring the user to often consult multiple manuals. Also, 
within each manual, key details needed to perform simple processes are 
scattered about and not well documented; even for those who are 
experienced in using such applications. SAS User Group International 
(SUGI)/SAS Global Forum publications are somewhat more useful. 
However, they do not always focus specifically on applications in 
biomedicine. There are some excellent SUGI publications such as 
“Threads Unraveled: A Parallel Processing Primer” which gives an 
excellent description of parallel processing (Shamlin, Threads Unraveled: 
A Parallel Processing Primer. 2004). However, such publications give no 
details on how to implement such processes in SAS. Conversely, there 
are other HPC related papers which do give technically correct 
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descriptions, are sometimes brief , leave out many key features and do 
not make concrete conceptual links (Stokes, Bradstreet and Hill 2002). For 
example, good parallel processing primers rarely are extended to include 
distributed grid computing and grid computing primers (or technical 
manuals) almost completely omit any discussion of multi-core parallel 
processing. Also, most grid computing or papers which address scaling 
out are focused on sending processes to remote machines focuses almost 
entirely on dedicated servers.  
The goal is to provide a context within which the processes 
presented can be useful to biomedical researchers as well as design 
templates to make it easier for analysts to more easily implement such 
features. Furthermore, with the prevalence of multi-core chips in almost 
every computer hardware application today, it is believed that a much 
more informative discussion of how to layer multi-core parallel processing 
with distributed grid computing is needed. This is because remotely 
submitting a job to a modern platform will almost always be going to a 
multi-core system. Taking advantage of the ability to scale out to a grid 
cannot be fully utilized without also being able to ensure the process will 
be processed in parallel once it reaches the grid or other machine. These 
computer tools, while not solutions to unraveling the complex world 
around us in and of themselves dramatically increase the performance 
and efficiency of quantitative analyses of biomedical data.  
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A few key HPC related processes which are highly useful for 
addressing current computational challenges in biomedicine are selected. 
The goal is also to provide a context within which the processes we 
present can be useful to biomedical researchers as well as how to simply 
implement them. Furthermore, with the prevalence of multi-core chips in 
almost every computer hardware application today, we believe that a 
much more informative discussion of how to layer multi-core parallel 
processing with distributed grid computing is needed. This is because 
remotely submitting a job to a modern platform will almost always be going 
to a multi-core system. Taking advantage of the ability to scale out to a 
grid cannot be fully utilized without also being able to ensure the process 
will be processed in parallel once it reaches the grid or other machine.  
Methods: 
Database Integration and Interfaces: 
 The concept of database integration ostensibly deals with 
connecting an analytics package directly to a database management 
system (DBMS) such as MS SQL, MySQL, Oracle or others. Database 
systems provide a number of benefits for the efficient storage and 
management of data – efficient use of storage space, data security, 
streamlined information persistence and retrieval workflow, rapid data 
retrieval through the use of indexes, etc.   
 The SAS package that enables users to make database 
connections is SAS/ACCESS. SAS/ACCESS is comprised of a collection 
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of interfaces. Although all interfaces operate in a similar way, each 
interface is specifically designed to connect to or work with a specific 
DBMS. Ostensibly the way SAS/ACCESS works is by translating SAS 
commands into the language of the specified DBMS. The request is then 
sent in the appropriate language, usually a variant of Structured Query 
Language (SQL), to the DBMS and the data is returned to the SAS 
system. There are two primary ways of connecting to a database. One 
method is by using the SAS/ACCESS library engine and libname 
statement. The second method to access a DBMS is via the pass-through 
facility. Each of these methods has its own advantages and 
disadvantages.  
 When utilizing the library engine in SAS to interface with the 
database, performing operations on data is much more straightforward 
and usually requires less code to access data. A single libname statement 
is sufficient to access data. In this respect, when specified properly, 
accessing a table in a DBMS is the same as accessing any other file in a 
SAS library. The benefit of this is that an end user does not need to know 
SQL or anything about databases to work with the information they need. 
The advantage to using the pass through facility is that it more robust for 
optimizing queries when joining multiple tables or using summary 
functions. The pass through facility can also make use of indexes placed 
on columns in the DBMS in order to process queries faster. Furthermore, 
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unlike, the library access method, pass through is able to accept more 
than just ANSI standard SQL.  
 Database connectivity technology can be useful is for various types 
of biomedical data and studies, e.g., microarray studies or in public health. 
Microarrays are widely used in genomic and proteomic research. 
Depending on the array type and study being conducted, a microarray can 
take anywhere from hundreds to millions of measurements from a 
biological sample. Within a specific study, measurements are usually 
taken from multiple individuals and thus produce large amounts of data; 
sometimes multiple gigabytes or even in excess of a terabyte. These data 
are commonly stored in databases, which provide an efficient mechanism 
for managing the large data sets.  Without using a database interface, in 
order to extract meaning from the microarray data, usually by performing 
statistical analysis or data mining, data would have to be exported from 
the DBMS. This creates two sources of inefficiency. First, it takes up hard 
drive storage space by creating flat text files (usually the type used by 
statistical analysis programs) with redundant information. Secondly, it 
takes time to export data and then import it into an analysis program such 
as SAS. The export/import process creates a significant bottleneck in the 
workflow process. Furthermore, exporting and importing data multiple 
times creates more possibilities for data integrity to be compromised.  
 An additional benefit is that database interfaces reduce the burden 
on IT and database maintenance staff. This is because once an IT person 
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sets up a database connection with a library reference engine, 
subsequently an end user or analyst is able to access information straight 
from the database without having to wait for IT to export for them a file 
from a database. Beyond this, there is no recurring need for an IT person 
to export a new dataset every time an update is made to the database. 
The analyst can simply access the database via a library in SAS and 
perform an analysis; thus streamlining workflow. Although there will 
probably be relatively little updates to the data made with microarray 
studies, an insurance company, hospital or public health entity may have 
updates to their database multiple times a day. Directly interfacing with a 
DBMS will help approach real time data analysis.  
 The process of physically integrating SAS/ACCESS with a 
database is quite simple. Once the ACCESS module for a specific 
database is installed a user can set up a database connection with syntax 
or point and click. To point and click, right click in the library window and 
click “new”.  
In the engine pull down box, select the SAS/ACCESS engine for 
the database that a connection will be established with. Then fill in the 
necessary fields (in this case user name, password, database, server, port 
as well as other SAS specifiable options). Finally, click ok to create a new 
library containing the database information. The enable at startup box will 
automatically load the specified DBMS connection every time a user starts 
SAS. 
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 The following is example syntax and reference code for 
syntactically connecting to a MySQL database: 
 Libname user_specified_library_name  mysql user=user_name-
password=user_password database=user_database_name_to-
_connect_to server=mysql_server_name
 port=port_to_connect_to_mysql_database; 
 run; 
 quit; 
The italicized portions are generic placeholders which a user would 
fill in to syntactically make a connection. The; and run and quit commands 
are parts of the SAS programming language. Tables in a database can be 
pulled simply using the library and file name syntax. PROC SQL can also 
be used to join tables and extract complex sets of data. 
High Performance Computing Methods: 
 In addition to more robust data management procedures such as 
using databases, there are a number of simple coding and programming 
methods that can dramatically reduce the time needed to perform 
computationally intensive analyses. With terabytes of biomedical data 
being generated, the length of time required to effectively analyze this 
amount of data with traditional single thread processing can be very large. 
Additionally, many processes in biomedicine lend themselves nicely to 
parallel processing. For example, peptide, genotype and gene expression 
microarray data often necessitate repeating analyses tens of thousands or 
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millions of times for each measurement on the chip. Public health data 
often requires repeating the same analyses on different datasets or 
separately for different subpopulations. Biomedical data across multiple 
domains may require running similar analyses under different assumptions 
or model specifications. Beyond repetition of tasks, any program in which 
individual pieces can be processed simultaneously or all of the data from 
one step is not needed for the next step to start (ability to overlap). High 
performance computing (HPC) methods presented can be of use. 
Since most new computers today make use of multi-core 
architecture, using the methods presented will help to make full use of the 
resources available to researchers without requiring a large financial 
investment in hardware. The sections below outline some of the HPC 
implementations available in SAS.  In SAS, pipeline parallelism, multi-core 
parallel processing and distributed grid processing are all features of the 
SAS/Connect package. Much of the syntax between these three 
processes is structurally quite similar. All three can be mixed and matched 
to best suit the needs of a given project. Additionally, all of these methods 
can be implemented when reading data from a database as described 
above. Although this dissertation focuses on SAS, again, other analytic 
programs are capable of doing similar things. The focus and goal is to 
illustrate a number of methods that are becoming more commonplace in 
analytic packages that can be highly useful to biomedical researchers 
without the need for a highly technical programming background. 
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Pipeline Parallelism: 
The first of the high performance computing related methods we 
will explore is pipeline parallelism. In its simplest form, pipeline parallelism 
uses TCP/IP ports on a computer to ‘pipe’ output from a process or step to 
a subsequent process or step in an analysis.    
Pipeline parallelism provides a number of advantages. First, and 
most obvious, is that this reduces intermediary writes to a hard drive. This 
is significant because writing large quantities of data to a hard drive and 
having to subsequently read it, is often one of the slowest steps in an 
analysis. This is because hard disk input/output (I/O) is usually orders of 
magnitude slower than processing data in memory. A second benefit of 
pipeline parallelism is the ability to process sequential processes in a 
more parallel fashion. Often times subsequent steps in an analysis do not 
need all of the information from the previous step to start working. For 
example, on a peptide microarray, thousands of regression models may 
need to be run to analyze the significance of each peptide and a 
subsequent step may be to merge all of the results into a single data file. 
The merging or union of the individual results step does not need to wait 
for the thousands of individual regressions to finish before starting. By 
using pipeline parallelism, regression outputs as they finish can be piped 
directly into a data step merging the results. 
 Despite the benefits of pipeline parallelism, there is a cost 
associated with it. For each pipe, there is an associated signon and signoff 
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process. Signon and signoff commands initiate and stop, respectively, 
links between local and a remote SAS sessions. Actions such as data 
steps piped to a sort procedure can be accomplished very efficiently with 
pipeline parallelism. Although looped regression equations and other more 
complex models can sometimes can benefit pipeline parallelism, the 
tradeoff between traditional read and write times need to be balanced 
between signon and signoff times. Generally, the larger the output form a 
given process, the greater the increase in overall performance will be. This 
is because the cost of a signon and signoff tasks relative to the overall 
process is reduced. With process producing large output, piping can often 
be more efficient than other methods of aggregating data; such as 
merging the data afterwards or a loop to run multiple SQL union 
procedures. Also, output from one process can be used as input in a 
subsequent process when building complex algorithms. A number of 
factors such as model complexity, amount of data being piped, overall 
memory utilization and overall computer load all likely play a role in 
determining the overall performance of piping; especially when piping 
output from one analytic procedure into another. 
 In the sample syntax below, three regression equations are 
performed and the output is piped into a single dataset as they are 
completed. The options autosignon=yes command is used to have SAS 
automatically open a TCP port for piping rather than having to specify 
signon task1, etc. The rsubmit statement is the basic SAS command for 
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remotely submitting a command, e.g., to open a port, to a specific 
processor or another machine. Wait=no tells SAS to execute the 
command immediately. Sysrputsync=yes is used if one was to nest this 
inside of a macro. This ensures that the macro variables would be 
updated. The SASCMD is a command used to specify options related to 
the remote submission.  Each rsubmit statement is closed with an 
endrsubmit statement. Everything nested between these two bocks is 
what is remotely submitted.  
Optionsautosignon = yes; 
 
rsubmit task1 wait=no sysrputsync=yes SASCMD="!SASCMD"; 
libname out1 sasesock":9001"; 
libname simtemp "c:\simtemp"; 
 
proc reg data=simtemp.ttest COV OUT 
OUTEST=out1.tstats1 tableout MSE; 
model class = score1; 
run; 
quit; 
endrsubmit; 
 
rsubmit task2 wait=no sysrputsync=yes SASCMD="!SASCMD"; 
libname out2 sasesock":9002"; 
libname simtemp "c:\simtemp"; 
 
proc reg data=simtemp.ttest COV OUT 
OUTEST=out2.tstats2 tableout MSE; 
model class = score2; 
run; 
quit; 
endrsubmit; 
 
rsubmit task3 wait=no sysrputsync=yes SASCMD="!SASCMD"; 
libname out3 sasesock":9003"; 
libname simtemp "c:\simtemp"; 
 
proc regdata=simtemp.ttest COV OUT 
OUTEST=out3.tstats3 tableout MSE; 
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model class = score3; 
run; 
quit; 
endrsubmit; 
 
rsubmit task4 wait=no sysrputsync=yes SASCMD="!SASCMD"; 
libname in1 sasesock":9001"; 
libname in2 sasesock":9002"; 
libname in3 sasesock":9003"; 
libname simtemp "C:\simtemp"; 
 
data simtemp.final_merged; 
set in1.tstats1 in2.tsats2 in3.tstats3; 
run; 
quit; 
 
endrsubmit; 
 
signoff task1; 
signoff task2; 
signoff task3; 
signoff task4; 
 
 Within the rsubmit block, we need a unique name for each remotely 
submitted process. In this case, task1 task2, andtask3 are used. The 
libname statements are ostensibly what define the syntax as pipeline 
parallelism. A libname needs to be set to specify the TCP port SAS will 
open. This is done with the sasesock “:xxxx” command. The name of the 
library is arbitrary but out1 out2 and out3 were used here because this is 
the step in which we were outputting results. When processing remote 
statements, SAS does not natively inherit libraries from the base SAS 
session so libraries used in a rsubmit block must be manually specified. 
This is done in the second libname command in each rsubmit block; 
although the ordering of libname statements is arbitrary. Output files need 
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to be specified to go to the library associated with the TCP port. In this 
example, the regression coefficients are output via the outest command to 
out1.tstats1 and so on. In the rsubmit4 block, the aggregation takes place. 
This block works in a highly similar way to the others. The only major 
difference is that the output library ports from the other rsubmit blocks are 
defined as input libraries in this rsubmit block. The naming is arbitrary of 
the library but the ports used in above blocks must be used in the later 
block of SAS is to make a connection to use the incoming data. After the 
final rsubmit block, a signoff statement is needed to close the port. There 
is not autosignoff option. It is important to note that the number of rsubmit 
blocks should not dramatically exceed the number of cores a computer 
has. The role of cores in this syntax will be discussed more below in the 
section on multi-core parallel processing. Although we present sample 
code for a t-test, piping is often more efficient when processing large 
amounts of output. This is because the associated input from a pipe can 
become cumbersome to program when a large number of repetitive tasks 
are done. We present piping in the context of a statistical test to 
demonstrate the robustness of the procedure; especially since the use of 
piping in other contexts such as data sorting is well documented in the 
SAS manuals and literature.  
Multi-Core Processing: 
 Multi-core parallel processing is perhaps one of the most powerful 
tools to aid in processing large amounts of biomedical data. Expanding the 
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number of processors and local system resources is often referred to as 
scaling-up. Although new programming languages and tools are starting to 
place more of an emphasis on threaded and multi-core programming, 
current languages in wide use such as Java are often difficult and 
cumbersome to perform multi-core and threaded programming. 
SAS/Connect is a simple and intuitive package that allows for easily 
parallel programming. The SAS/Connect rsubmit statement makes the 
task of creating multiple threads to submit to a unique core very simple. 
Given the size of many biomedical datasets utilizing all of the cores in a 
computer can dramatically reduce processing time. The exact amount of 
reduction will depend on the amount of the overall analysis that is able to 
be parallelized. As the amount of the program which can be parallelized 
increases, the time reduction from parallelization increases. Regardless of 
how much of the program can be parallelized, the ability to have a 2-8x 
increase in number of available processors provides a substantial benefit; 
especially when considering the low cost of multi-core computers today. 
 Below is syntax which demonstrates the use of multi-core parallel 
processing. In the syntax below, two processors are used to perform 
10,000 regression models with 5,000 per processor. A SAS macro and a 
do loop is used to iteratively loop through different regression equations. 
The syntax for creating multiple threads and making use of a multi-core 
PC is quite similar to that used in the pipeline parallelism. This is because 
each different task in piping is a separate thread and thus the reason why 
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it is not recommended for the number of threads to exceed the number of 
processors. All of the syntax nested between a rsubmit and endrsubmt 
block will create a new thread that is sent to a specific processor. The 
names task1 and task2 are arbitrary but must be different for each rsubmit 
statement and an associated signoff of each rsubmit is necessary. In this 
example, the rsubmit statements will signoff as they finish. However, the 
command _waitfor_=all; can be used to have SAS wait for all of the 
processes to finish before continuing. Here, we specify the library of files 
being used for analyses overtly in the libname statement. There is an 
inheritlib command which will allow SAS to inherit libraries  
 More information can be found in the SAS Macro language manual 
about the specifics of macro programming. Macros are user defined mini 
programs or blocks of code that can be reused.  However, in the example 
below, the block between %macro regs() and %regs(); is a single macro. 
The %mend ends the macro program. The block between %do and %end 
is the do loop. The ods output statement inside the do loop tells SAS to 
output parameter estimates to the file test.paramsx&i. In the do statement 
the counter variable i was used. Everywhere in the macro that &i appears, 
SAS substitutes the value of i for that pass through the loop. 
Options autosignon=yes; 
 rsubmit task1 wait=no sysrputsync=yes SASCMD="SAS"; 
  libname test 'c:\test'; 
  %macroregs(); 
  %do i = 1%to5000; 
  PROC reg data=test.test1; 
  model y=peptide&i; 
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  ods output ParameterEstimates = test.paramsx&i; 
  run; 
  quit; 
  %end; 
  %mend; 
  %regs(); 
 endrsubmit; 
 
 rsubmit task2 wait=no sysrputsync=yes SASCMD="SAS"; 
  libname test 'c:\test'; 
  %macro regs(); 
  %do i = 5001%to10000; 
  Proc reg data=test.test1; 
  model y=peptide&i; 
  ods output ParameterEstimates = test.paramsx&i; 
  run; 
  quit; 
  %end; 
  %mend; 
  %regs(); 
 endrsubmit; 
 
signoff task1; 
signoff task2; 
 
Distributed and Grid Parallel Processing: 
Beyond single multi-core parallel processing on a single PC, the 
syntax can easily be extended to remotely submit a multi-core parallel 
program to a remote machine. When utilizing other computing resources 
networked to a host computer, this is often referred to as scaling out. A 
simple and inexpensive way to scale out is to use other computers 
(remote machines) running SAS. The remote machine can be a server or 
another PC running SAS. High performance computing clusters (HPC) are 
a tremendous resource for analyzing biomedical data. However, there is a 
large cost often associated with HPC clusters and using them requires 
specialized knowledge . Many HPC clusters require the code to be 
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submitted in languages such as C or Fortran and via a secure shell 
program. Given the complexity of many of today’s statistical analyses, 
programming, for example, a mixture model using maximum likelihood 
estimation with robust standard errors is extremely complex. Beyond the 
difficulty, the time needed to program such a model in C or Fortran could 
be prohibitive. Furthermore, licensing for software on HPC is often very 
expensive.  Often times, research institutions or labs will have SAS on 
multiple PCs. Being able to remotely submit programs to other PCs will 
allow users to approach the processing power traditionally only available 
to researchers with access to HPC clusters. For example, 3 Intel I7 PCs 
could theoretically provide more than 200,000 CPU hours (3 x 8 x 24 x 
365 = 202,752) of processing time per year.  
Below is syntax for submitting programs to another PC running 
SAS. In this program, the multi-core parallel program is submitted to 
another PC and the results are sent back to the host machine. In addition 
to the syntax provided, the SAS Object Spawner needs to be running on 
the remote machine.Spawner.exe is included with SAS/Connect.  
Filename rlink "C:\Program 
Files\SAS\SASFoundation\9.2\connect\saslink\tcpwin.scr"; 
%let node=XXX.XXX.XXX.XXX; 
signon remote=node; 
libname test "c:\test"; 
rsubmit remote=node wait=no; 
libname test 'c:\test'; 
proc upload inlib=test outlib=test; 
proc download inlib=test outlib=test; 
options autosignon=yes; 
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 rsubmit task1 wait=no sysrputsync=yes SASCMD="SAS"; 
  libname test 'c:\test'; 
  %macro regs(); 
  %do i = 1%to5000; 
  Proc reg data=test.test1; 
  model y=peptide&i; 
  ods output ParameterEstimates = test.paramsx&i; 
  run; 
  quit; 
  %end; 
  %mend; 
  %regs(); 
 endrsubmit; 
 
 rsubmit task2 wait=no sysrputsync=yes SASCMD="SAS"; 
  libname test 'c:\test'; 
  %macro regs(); 
  %do i = 5001%to10000; 
  Proc reg data=test.test1; 
  model y=peptide&i; 
  ods output ParameterEstimates = test.paramsx&i; 
  run; 
  quit; 
  %end; 
  %mend; 
  %regs(); 
 endrsubmit; 
 
signoff task1; 
signoff task2; 
 
endrsubmit; 
signoff node; 
The filename rlink provides the location of the file tcpwin.scr. This is 
a script which tells SAS how to signon to a remote PC. The path to the file 
needs to be provided. The %let statement specifies the local IP address to 
the remote pc. The signon command remote=node is what tells SAS to 
signon to the remote PC. In SAS, a signon remote= command must have 
a SAS variable instead of an IP address. The %let command sets node 
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equal to the IP address. The syntax node is arbitrary and anything could 
be used. For example, PC1, PC2, PC3 could be used if submitting 
multiple blocks to multiple PCs. The signon process is ended with and 
endrsubmit and signoff statement. The signoff statement must specify 
which PC to signoff of; in this case the PC named node. 
As within an rsubmit statement, the remote SAS session on another 
PC will not inherit the host system’s libraries. Therefore, the library needs 
to be defined. Here we specify the library test to be located in c:\test. The 
location of this file is on the remote PC not the host PC. A database 
connect could be used here. However, if a database is not used the files 
for analysis either need to be manually copied into the library on the 
remote PC or uploaded via syntax. PROC upload is specified after a 
signon statement and is used to upload a complete library (or specific files 
in a library by using a where clause) to a remote PC. The inlib is the library 
on the host pc and the outlib is the library on the remote PC. When 
processing files on the remote PC, SAS will save files on the remote PC. 
The files will often need to be brought back to the host PC for aggregating. 
This is accomplished via the proc download command. In proc download, 
the inlib is the library on the remote PC and the outlib is the library on the 
host PC that files will be copied to. Once complete, the files will be 
available for processing or viewing on the host pc. 
We recommend using a local area network for processing for a few 
reasons. First, using local area network IP addresses reduces the 
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complexity which can sometimes be associated with external firewalls. 
Secondly, local area networks often have much faster transfer rates. New 
PC’s often have a gigabit per second transfer rates for hard wired local 
area networks. If a large amount of data is being transferred, having the 
fastest possible network connection between computers will minimize lag. 
Results: 
 To test the gain in performance for multicore and multicore 
distributed processing we use a Monte Carlo simulation to study the 
classical Behrens Fisher problem. In a Monte Carlo simulation, data is 
generated and a specific test is conducted a large number of times. The 
Behrens Fisher problem is a statistical debate without an analytic solution 
relating to the effect of unequal variances on the T-Test. In this simulation 
we study 3 sample sizes each with 3 different variances for a total of 9 
conditions per replication. We replicate the simulation 10,000 times. In 
addition, SAS runs an equal and Satterthwaite unequal variance T-Test in 
the standard proc ttest procedure. This results in 90,000 executions of the 
proc ttest procedure and 180,000 tests being conducted. The output from 
each run is saved and aggregated using the SQL union operator.  
 We test 3 different uses of multicore processing to illustrate the 
performance gains above the baseline of a single core process without 
parallelization. The machines used in this analysis were PCs each with 
one 2.5 GHz Xeon processor and 16gb of ram. PCs are connected on a 
gigabit Ethernet. First, a baseline test was run using a single thread and 
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core to process the entire simulation.  In the second study all 4 cores were 
used on a host PC to run the simulation. Both the T-Tests and SQL unions 
were split into 4 equal parts. The third approach used both a local PC host 
and a second remote machine to process the simulation resulting in a total 
of 8 processors being used and the task being split into 8 equal parts. The 
same dataset was used for these performance studies. The benchmark 
test results are summarized in Table 1. 
Table 1 HPC Execution Times for the Simulation Benchmark Test  
 Single Thread 4 Threads 
One PC 
8 threads on 
2 PC’s  
T-Test’s Only Time 18 minutes 28 
seconds 
5 minutes 39 
seconds 
2 minutes 53 
seconds  
Total Time 
(including I/O) 
87 minutes 6 seconds 28 minutes 
14 seconds 
12 minutes  
8 seconds 
In this simulation we notice that the total execution time for 8 
threads on 2 PC is less than half the time of 4 threads on a single PC. 
However, this is one example of a common occurrence encountered when 
working with large datasets in biomedicine where breaking tasks down 
into smaller pieces can have an nonlinear and higher order increase on 
performance. In this simulation we merge the results using a loop and an 
SQL union procedure. By breaking the task down into smaller pieces, the 
time to process each join is substantially reduced. This is because the 
load and write time for smaller files is significantly faster. This effect is 
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especially apparent towards the upper end as more results are added to 
the merging file and the size of this file grows. Although there are likely 
more efficient ways to integrate the simulation results than presented 
here, we chose this method to illustrate the fact that while parallel and 
distributed processing can dramatically improve performance. Careful 
attention to program design and thinking about the entire workflow 
process are often significant moderators of performance gains. 
 The advanced multi-core processors on the market today provide 
vast increases in the potential computing power available to researchers. 
Multi core processors and technologies such as Intel’s Hyper threading 
(which ostensibly allows for 8 simultaneous threads on a quad core chip) 
can be procured relatively inexpensively. A competent quad core desktop 
as well as one with Hyper threading can be procured for at or under 
$1,000. By using the parallel processing and distributed computing 
infrastructure in SAS researchers can leverage the processing power of 
modern computers and expand their research with relatively little financial 
expenditure.  
210,240 CPU hour per year are theoretically available from 3 new 
Intel based PCs with Hyper threading technology (8 cpu hours per pc x 24 
hours/day x 365 days/year x 3 pcs = 210,240 cpu hours/year). Assuming a 
total cost of $5,000 for purchasing 3 such PC, including monitors and 
ancillary equipment such as networking supplies (a purposely high 
estimate), SAS licensing not included, results in approximately 0.024 
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cents per CPU hour if the total cost of the computers and equipment 
purchased is fully depreciated in a single year. However, it is likely that the 
computers and equipment would last considerably longer. Cloud based 
computing systems such as Amazon EC2 are at a minimum 5 times more 
expensive per CPU hour before factoring in the cost of data transfer and 
hosting. Additionally, SAS cannot be run on many cloud based clusters 
and the licensing to run SAS on a HPC supercomputing cluster is an 
additional cost. While SAS licensing costs are quite variable depending on 
a number of factors such as the packages chosen, we expect that the 
additional cost to license SAS on a second or third PC would be 
cumulatively less than the cost to purchase licensing to use on a HPC 
supercomputing cluster.  
However, there are still clear benefits using HPC clusters which are 
undeniable. For one, the entire 210,240 CPU hours could in theory be run 
in much less time than one year on a large HPC cluster. Additionally, HPC 
clusters are also likely to have more access to memory for complex 
models which may not always be available to researchers using high end 
desktop computers. Nonetheless, with new computers able to support 24+ 
GB of memory, we suspect that for many applications the need for 
significantly more memory will be limited to highly complex and 
specialized cases; and cases requiring such capacity will be so large and 
complex as to already be beyond the scope of this dissertation.  
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Discussion: 
The vast amounts of data being generated in biomedicine and the 
health care industry today are generating a number of analytic and 
technical challenges. One major problem is how to effectively manage and 
analyze the data in a timely fashion. The techniques and methods 
including database integration, pipeline parallelism, multi-core and 
distributed grid computing can help dramatically increase the speed of 
analyzing biomedical data. As the size of biomedical data sets grow, e.g., 
higher density microarrays or high-throughput genomic sequencing, 
understanding how to maximize the efficient use of available computing 
resources will only become more of a challenge. In addition, being able to 
increase the speed and performance of analysis of biomedical data, these 
processes will aid in increasing efficiency, streamlining workflows and 
promoting breakthroughs in biomedicine which help to ameliorate the 
quality of life for millions of individuals. The relatively inexpensive cost of 
new computers may for many researchers provide a distinct cost 
advantage over other HPC options or allow researchers to maximize the 
resources already at their disposal. Although the methods described here 
will not completely surpass traditional HPC cluster, we believe that these 
methods provide a significant advantage in terms of ease of programming 
and enabling inexpensive access to computing power that will be a 
valuable resource and appealing alternative for many researchers in the 
biomedical domain. 
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Conclusion: 
 This chapter demonstrates a set of useful computer science tools in 
a format (SAS) that is familiar to many analysts. To further illustrate with 
more concrete examples of how these methods are useful, each 
subsequent chapter gives an explanation of how these methods were 
used to facilitate the research. Utilizing these methods will help reduce 
storage needs and processing time for large biomedical datasets or of 
complex iterative models.  Such performance gains will increase the 
speed of biomedical data analysis as well as the speed of biomedical 
research more generally. 
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CHAPTER 3 
MONTE CARL SIMULATIONS  
Chapter Overview: 
 This chapter presents the use of Monte Carlo simulation 
methodologies to help pick the most appropriate model which minimizes 
bias and error due to violation of model assumptions. While Monte Carlo 
methods are generally applicable to all violations and for testing new 
model estimation routines, this chapter specifically focuses on violations of 
homogeneity of variance. This is because homogeneity of variance is 
among the most common violations in biomedical data and can easily lead 
to dramatically incorrect type 1 and type 2 error rates. The real world 
example involving immunosignature data shows that this violation can 
easily result in type 1 error rates in excess of 60%; an order of magnitude 
higher than the standard 5%. Additionally, given the size of biomedical 
datasets, there can be a range of violations across the dataset stemming 
from no violation in some cases to massive violations in others. As a 
result, sampling methodologies are proposed as a computationally 
efficient tool for screening the extent of violations and to help inform the 
design of a Monte Carlo simulation that will maximally represent the 
structure of the dataset.  
Problem Abstract: 
 Statistical models are based on a number of assumptions such as 
homogeneity of variance.  When model assumptions are violated the 
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models do not yield accurate or predictable results. Additionally, in the 
case of heterogeneity of variance or with complex iterative models such as 
those which utilize Maximum likelihood, there is no exact analytic solution 
that can be derived for how the violation will impact model performance. 
As a result, determining the most appropriate correction is not always 
clearly defined and is difficult even in the univariate case. This challenge is 
made significantly more complex by modern biomedical data such as 
microarrays where there are thousands or millions of comparisons need to 
be performed. As a result, Monte Carlo Simulations and sampling 
methods are advocated to help pick the model which that provides the 
most accurate results across the entire range of the data. 
Background: 
The results of the analysis of complex biological and biomedical 
data are not always correct. This is not because of any malicious intent by 
researchers to make the results of their analyses incorrect but rather 
because statistical and mathematical models used to conduct the analysis 
are sensitive to the assumptions underlying their design.  Thus, just 
because a computer gives a researcher an answer does not mean it is the 
correct answer; in the same way a student punching numbers into a 
calculator is not guaranteed to come out with the correct answer just 
because he or she used advanced technology. In order to extract meaning 
from analyses of biomedical data, whether we are using simple or 
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complex modeling techniques, we need to ensure that the most 
informative analyses are being done.  
A Monte Carl simulation is a study in which a large number (usually 
thousands) of datasets are randomly generated with a given distributional 
property and a statistical test is performed on each dataset. The results of 
the test are aggregated and the performance of the test can be studied. 
Since there are many cases such as unequal variances and iterative 
models in which no exact analytic solution can be precisely derived, Monte 
Carlo simulations have become the defacto gold standard for 
understanding model performance (Fan 2002).  
The challenge of big data has made the task of picking the correct 
model exponentially more difficult. Beyond the single test or comparison 
case, modern biomedical datasets often have tens of thousands or 
millions of comparisons which need to be investigated; specifically 
microarray datasets. Given the difficulty in making this decision for one 
comparison, it is vastly more complicated to pick a correct method for use 
across thousands or millions of contrasts. There is no single method which 
is ideally suited to all cases (Keppel and Wickens 2007) (Cohen, et al. 
2002). Given the natural variability by chance alone across thousands or 
millions of contrasts, without looking at the data in a thorough way, it is 
ostensibly impossible to have any idea which method is the most accurate 
across the state space of the dataset. As a result, the use of sampling 
methodologies to gain an understanding across of the range and 
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magnitude of violations across entire datasets combined with Monte Carlo 
simulations to pick the best method is strongly advocated.  
Statisticians have been debating one such case of violation of 
statistical model assumptions known as the Behrens Fisher problem for 
more than 80 years with no definitive solution yet to emerge. A Behrens 
Fisher problem arises when trying to estimate the difference in two means 
when groups have unequal variances because point estimates, hypothesis 
tests and type 1 and type 2 error rates can become unreliable (Behrens 
1929) (Seock-Ho and Cohen 1995). While there are many approaches 
which have been proposed, many of the classical methods such as 
Fisher’s fiducial theory (R. Fisher 1935), Jersey Neyman and Egon 
Pearson’s sampling proposal (Neyman and Pearson 1928) or a Bayesian 
method proposed by Harold Jeffreys (Jeffreys 1940), all of these solutions 
tend to give differing answers; especially with small sample sizes (Seock-
Ho and Cohen 1995).  
A similar problem arises in linear models such as Student’s T-Test 
when violations of normality exist. In 1960 John Tukey noted that there are 
multiple cases in which normality can dramatically bias confidence 
intervals, effect size measures and reduce power (Tukey, A survey of 
sampling from contaminated distributions 1960). Tukey and McLaughlin 
proposed a method of trimmed means (Tukey and McLaughlin 1963). As 
with the Behrens Fisher problem, no single best method has arisen 
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because a closed form analytic solution does not exist (Seock-Ho and 
Cohen 1995) (Wilcox 1995).  
One method which has become widely used to estimate solutions 
when an exact analytic solution does not exist, the computation time for an 
exact solution is excessive and to understand the behavior of statistical 
models is a Monte Carlo simulation. In the simplest form of a Monte Carlo 
simulation, many datasets (often thousands with modern computer 
experiments) are randomly generated and a statistic is tested on each set. 
The results are then aggregated to obtain an approximate estimate of 
model behavior.  
Although the first formal publication linking repeated random 
sampling to the term Monte Carlo was by Nicholas Metropolis and Stan 
Ulam in 1949 stemming from their work on the Manhattan project 
(Metropolis and Ulam 1949). One of the earliest uses of a Monte Carlo 
method was an 1872 report by Asaph Hall in the Journal Messenger of 
Mathematics (Hall 1872). Hall reports Captain O.C. Fox randomly throwing 
wire pins at a wooden board with equidistant parallel lines while 
recovering from battle wounds during the Civil War (Hall 1872). Captain 
Fox used the values from repeated tosses to calculate the approximate 
value of pi (Hall 1872).  
William Sealey Gossett actually used a method ostensibly similar to 
a Monte Carlo method in much of his early work to validate his theoretical 
ideas about the T-Test and distributions of correlations. Many of Gossett’s 
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works used random sampling methods in a similar way to which modern 
researchers use Monte Carlo simulations (W. S. Gossett 1908) (W. S. 
Gossett 1908) (W. S. Gossett 1921). 
Again, the modern terminology for Monte Carlo experiments came 
out of work by Stan Ulam, Nicholas Metropolis and Jon Von Neuman from 
their work at Los Alamos National Laboratory in the 1940’s from their work 
on nuclear weapons development (Metropolis 1987) (Metropolis and Ulam 
1949). During World War II,one of the earliest computers called ENIAC 
was originally built and used for nuclear research. Because of the new 
found ability to compute numbers more rapidly, Ulam suggested 
resurrecting older statistical ideas which had been brushed aside because 
of the computational time intensity and difficulty (Metropolis 1987).  
Along with Metropolis and Von Neuman, the decision was made to 
emply ENIAC and statistical methods to model neutron multiplication and 
diffusion in fissionable material. This was important  because, at the 
quantum level, there is inherent randomness and the complex geometry 
inhernt in the design of nuclear reactions makes modeling neutrons 
difficult. When a block of fissionable material is compressed to a sufficient 
state that it reaches critical mass, a nuclear chain reaction is started. As 
atoms are split or combined (depending on the type of reaction) neutrons 
are released which then split other atoms increasing the energy yield of 
nuclear reactions. The team selected a random distribution of neutrons 
surrounding a spherical core of fissile material with a random velocity and 
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then tested the path and history of a neutron. This was repeated 
numerous times until a statistically valid model was generated (Metropolis 
1987).  When working to develop the Monte Carlo method Metropolis 
suggested the name Monte Carlo in part related to an uncle of Ulam who 
was always borrowing money to go to the grand casion’s and Monte Carlo 
(Metropolis 1987). The casino games are ostensibly games of chance, 
which is related to the random sampling or generation of data, the name 
Monte Carlo stuck (Metropolis 1987). 
In the half century since the formal development of Monte Carlo 
methods by Metropolis, Ulam and Von Neuman, the method has found 
wide spread use in many areas of statistics and mathematics. These 
range from estimating differential equations, entire statistical methods 
such as a Markov Chain Monte Carlo based on the Monte Carlo method 
as well as the enormous use to validate statistical methods (Fan 2002). 
There are literally thousands of statistical articles which use Monte Carlo 
simulations to test the effectiveness or validity of a given statistical 
method. In fact, the approach is so prevalent that entire Monte Carlo 
packages are intergrated into advanced statistical software such as Mplus 
(Muthen and Muthen 2011). While Monte Carlo simulations are often used 
to test the performance of statistical models in methodology papers, they 
are rarely if ever used by researchers to pick the best model for their given 
experiment.  
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Given the frequency, or almost certainty with which biomedical 
datasets violate major assumptions of classical linear models, performing 
a basic Monte Carlo to pick the best method or correction (ie. T-Test 
versus Satterwaithe correction etc) should be as commonplace as 
background subtraction, normalization and transformation in microarray 
processing.  
Metropolis, Ulam and Von Neuman were able to resurrect ideas 
from Gossett and others about random sampling because of computers. In 
the decdes since their early work at Los Alamos, Monte Carlo simulations 
have become commonplace to estimate partial differential equations, as 
part of Markov Chain Monte Carlo methods and to test statistical methods. 
In statistics, Monte Carlo simulations have historically been intensive 
research problems that even with computers could take months or years. 
However, microprocessors and high performance computing methods, 
such as those advocated in chapter 2, including parallel procesing and 
distributed grid processing the time can now be measured in hours or 
minutes; if the question is sufficiently focused.   
Ensuring the test conducted is given the expected results or 
performing under the expected parameters (ie. 5% type 1 error rate) is 
critical to extracting meaning from complexity in biomedical datasets. 
However, the process is made more difficult by big data. This is because 
the question is often one of thousands or millions of comparisons. As a 
result, the question is not simply of which model is best for a single 
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comparison but rather which will perform most robustly across the range 
and surface of the entire dataset.  
It is common practice in text books to suggest that statistical texts 
advocate running tests of model assumptions as part of a standard 
workflow (Keppel and Wickens 2007) (Cohen, et al. 2002) (Tabachnick 
and Fidell 2006). SAS implements a number of test procedures to test 
equality of variances. In proc ttest, the Folded-F method is a default 
output. PROC GLM for running regression or Analysis of Variance models 
offers a number of tests including Levene’s and the Brown Forsyth test 
(SAS Institute 2011). Both Satterthwaite and Welch robust tests are 
implemented in proc ttest and proc glm respectively. In fact, the 
Satterthwaite correction is generated by default in proc ttest.  
There are also many other ways beyond a t-test and a one way 
ANOVA to test whether there is a mean difference between two groups. A 
linear regression equation can use dummy codes (which will produce 
equivalent parameter estimates to ANOVA when grand mean effect coded 
since ANOVA is a special case of regression) as well as logistic 
regression. Weighted least squares and robust regression methods are 
also alternative ways of correcting heteroskedasticity (unequal variances) 
(Rao, et al. 2010). Additionally, there are multiple estimation methods 
available for logistic regression models in SAS (SAS Institute 2011). 
The fundamental design of many biomedical analyses will logically 
produce results with heteroskedastic or unequal variances. For example, 
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in a cancer study, if there is a common unerlying biomarker, whether it is 
an expressed gene, the presence of an antiboy or other marker, a group 
of cancer patients with the same type of cancer may be expected to show 
a similar response profile. Normal patients who do not have cancer or the 
condition in question might be expected to have a wider variation in the 
observed values of their responses if sampled from the population at 
random. This is because all of the population variability would be 
encapsulated in the normal samples whereas only a smaller subset of 
those who exhibit similar characteristics on a given trait would be 
observed in the cancer or condition samples. Conversely, it is also 
possible that normal patients will have a more similar response profile and 
those with a condition will have a wider variation. This could result in 
situations in which there is a relatively small homeostatic window and any 
response outside of that leads to a disease. Also, we may observe 
differences in variance structures based on sample size. If there is a large 
difference in variation it may simply be because a larger number of 
samples was obtained from a given group and the larger number of 
samples asymptotically led to a more normal distribution consistent with 
the central limits theorem.  
Ostensibly, it is not always clear that we can or should expect equal 
variances in biomedical studies. Combine this with big data concerns such 
as testing thousands or millions of variables (genes, peptides etc) and the 
probability is that there will be a number of observations for which the 
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assumptions are perfectly met and a number where they are egregiously 
violated; with everything inbetween. This might lead some researchers to 
suggest computing a different model for each observation or comparison. 
For example, one suggestion could be to run a basic ANOVA model with a 
test for equality of variances and if it is met then run the standard ANOVA 
otherwise run a correction or alternative method.  
There are a few issue with running different models for each 
observation. First, this would pose a massive increase in computational 
difficulty and run time. Secondly, a p-value, F or T statistic are not 
measures of effect size and cannot be compared across models (Cohen, 
et al. 2002). Some researchers might suggest that an effect size measure 
might be a more approprite method since they can be more easily 
compared and are less sample dependent than p-values F or T statistics. 
However, effect size measures also have their own set of model 
assumptions; many of which are the same as for traditional statistical 
tests. 
The original validation work by E.S. Pearson and others on the 
Pearson product moment correlation coefficient was done assuming that 
the correlatin was zero (Pearson 1929) (Pearson 1931) (Rider 1932). The 
work by E.S. Pearson and others early on demonstrated that the pearson 
prodcut moment correlation is highly robust when the correlation 
coefficient was zero or very nearly so, that unequal variances and other 
violations of normal theory (Pearson 1929) (Pearson, The Test of 
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Significance for the Correlation Coefficient 1931) (Rider 1932) (Haldene 
1949). Later research by Kowalski and others showed, using Monte Carlo 
simulations in Kowalski’s case that as the correlation coefficient increases, 
the bias of the correlation coefficient also increases (Kowalski 1972). 
Ostensibly, regardless of what method a researcher uses whether a 
classical statistical test, effect size measure or data mining technique, they 
are subject to some underlying assumptions and the premise that they are 
not likely to hold over the range of thousands or millions of observations is 
still a concern.  
One technical challenge posed by suggesting that researchers 
check assumptions across entire datasets is one of computational 
intensity. Simply running all of the comparisons can be computationally 
intensive to begin with and suggesting more tests beyond a simulation be 
run multiplies the computational burden. To help alleviate this concern, 
beyond the high performance computing methods discussed earlier, two 
suggestions are proposed. First, there is no need to run rigorous equality 
of variance tests and secondly, the use of sampling methodologies are 
recommended.  
The reason for not running a rigorous equality of variance test such 
as a Brown-Forsyth test is because it adds to the computational demand 
and really does not add much information. This is because such tests only 
tell a researcher if there is a violation and give no details about the 
magnitude of the violation (Keppel and Wickens 2007). A researcher will 
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then have to run univariate statistics above and beyond the equality of 
variance tests to get the input parameters to the Monte Carlo simulation. 
As a result, since univariate tests are going to be performed anyways, it is 
not necessary to add the step of a formal equality of variance test. 
However, if the researcher runs such test and notices small differences in 
the variances between two groups, individual equality of variance tests 
could be run in the rare even that a big dataset has thousands or millions 
of comparisons with very tiny differences in variances across all 
comparisons.  
Secondly, the use of sampling methodologies are highly 
recommended to take a subsample of the data. Sampling methods have 
been well developed in statistical literature and are easily implemented in 
many software packages such as SAS; including proc surveyselect, 
surveyreg, surveyfreq and surveylogistic (SAS Institute 2011). A number 
of different sampling procedures such as simple random sampling, 
stratified random sampling or cluster randomized samples can be taken 
from the dataset depending on the nature and structure of the data. For 
some complex studies, a multi-stage probability sample may be 
necessary; especially if the large study comes as part of a larger survey. 
The book Sampling: Design and Analysis 2nd Edition by Dr. Sharon Lohr 
provides an unsurpassed discussion and presentation of sampling 
methodologies and is an excellent resource for researchers (Lohr 2009). 
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Additionally, the book also emphasizes the use of SAS and provides 
extensive code examples. 
Model: 
Since much genetic and proteomic expression data in raw form is 
generally on a multiplicative scale rathre than a linear scale (assumed by 
most parametric statistical models), the first step in any genetic data 
analysis is background correction, normalization and log transformation to 
make the data as amenable as possible to general statistlcal models 
(Quackenbush, Causton and Brazma 2003). Because genomic data 
inherently violates these assumptions and no clear normalization process 
has been identified to always give a reasonable correction, it is 
questionable how often standard model assumptions are actually met and 
no formal meta analysis are known to have looked at the quesiton. As a 
result, it is imperative that researches test to ensure tha the models being 
used will produce accurate results.  
The procedure of using Monte Carlo simulations to determine 
optimal statistical tests was used in the immunosignaturing chapter 
discussed in chapger 5. The simulation work described in this chapter was 
the genesis behind using a Satterthwaite corrected t-test in the 
immunosignaturing chapter. The introduction to this chapter primarily 
focuses on the assumption of homogeneity of variance or 
heteroskedasticity as is sometimes referred to and type 1 errors (false 
positives). This is because linear models are usually more robust to 
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violations of normality than they are to violations of unequal variance and 
multi-level modeling corrections for violations of independence widely 
agreed upon (Keppel and Wickens 2007) (Raudenbush and Bryk 2001). 
Additionally, multi-level corrections for violations of independence are 
discussed in detail in the next chapter.  
 Immunosignaturing is described in chapter 5 in detail. As a basic 
summary, immunosignaturing is a microarray based technology for 
profiling humoral immune responses. Thousands of random 20 mer 
peptides were selected from a phage library to give broad coverage of 
human immune responses and are spotted onto a glass slide. Purified 
sera samples are applied to the array and antibodies, primarily IgG bind to 
the random peptides. When an antibody binds with a peptide it will 
flouesce when exposed to a laser; thus giving a measure of binding affinity 
(Johnson and Stafford 2009). 
 The study of interest using immunosignatures compared normal, 
single breast cancer tumors and second primary tumor samples with the 
goal of differentiating and the three groups as a diagnostic test (Brown, et 
al. 2011). Before running basic screening models across the more than 
10,000 peptides on the array, basic descriptive statistics were estimated 
and a random sample of the peptides were taken. A simple random 
sample of 500 peptides was taken and differences in variances for each 
group was calculated. The sample was taken using proc surveyselect in 
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SAS. The largest magnitude difference was approximately 6 fold between 
normal samples and a second primary tumor peptide.  
 Monte Carlo simulations were run using equal variances, 1, 2, 4 
and 6 fold differences between each of the three groups in univariate 
contrasts. Two datasets with sample sizes equal to those in the study (52 
for normal, 98 for single primary tumor and 21 second primary tumor 
samples). A scaling factor was used to increase the variance of one group 
by the given factor. Since type 1 errors were the primary interest, the 
means were simulated to be equal. SAS IML random number generator 
was used to generate the data. 2,000 tests were run for a standard T-Test, 
Satterthwaite T-Test, least squares regression, logistic regression as well 
as maximum likelihood regression and logistic regression with sandwich 
estimators. With a standard alpha level of 0.5, it is expected that by 
chance alone 100 tests would be significant. As a result, more than 100 
significant results would suggest a greater than 5% type 1 error rate. 
While not investigated in this chapter, power could also be studied. This 
would have been done by changing the mean difference of the two groups 
and then the percentage of significant tests would be equal to power; for 
the given magnitude difference.  
Results: 
 Table 2 shows that the simulation results for logistic regression 
outperforms standard ordinary least squares regression and a standard 
pooled T-Test with respect to type 1 errors. However, both maximum 
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likelihood regression and logistic regression with sandwich estimator 
robust standard errors as well as the Satterthwaite T-Test both 
significantly outperform the standard models; especially when the larger 
group has the smaller variance.  
Table 2 Monte Carlo Simulation Results 
 
Trial Varia
nce 
Logist
ic 
Robus
t SE 
Error 
Logist
ic 
Type1 
Error 
OLS 
Reg 
Type
1 
Error 
ML 
Reg 
Robust 
SE 
Type1 
Error 
Std T-
Test 
Type1 
Error 
Sattert
hwaite 
Type1 
Error 
cancer 
vs 
normal  
10 90 83 182 95 91 89 
cancer 
vs 
normal  
20 108 206 444 125 222 115 
cancer 
vs 
normal  
40 77 238 526 107 263 98 
cancer 
vs 
normal  
60 95 294 632 121 316 111 
cancer 
vs 
second  
10 111 86 210 131 105 104 
cancer 
vs 
second  
20 153 344 770 134 385 103 
cancer 
vs 
second  
40 159 567 1236 141 618 105 
cancer 
vs 
second  
60 141 643 1420 129 710 93 
normal 
vs 
cancer 
10 93 83 194 106 97 99 
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normal 
vs 
cancer 
20 94 37 86 111 43 110 
normal 
vs 
cancer 
40 63 14 32 96 16 92 
normal 
vs 
cancer 
60 74 18 40 103 20 101 
normal 
vs 
second 
10 88 80 188 103 94 93 
normal 
vs 
second 
20 119 233 556 120 278 85 
normal 
vs 
second 
40 96 306 760 129 380 100 
normal 
vs 
second 
60 78 349 858 132 429 99 
second 
vs 
cancer 
10 105 91 206 129 103 104 
second 
vs 
cancer 
20 84 4 14 104 7 96 
second 
vs 
cancer 
40 67 1 2 87 1 85 
second 
vs 
cancer 
60 80 3 5 106 12 103 
second 
vs 
normal 
10 101 84 228 130 114 114 
second 
vs 
normal 
20 75 28 74 121 37 112 
second 
vs 
normal 
40 63 4 18 111 9 109 
second 
vs 
normal 
60 54 3 12 102 6 93 
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The three corrective models show consistently performance with 
respect to type 1 errors. The Satterthwaite corrected T-Test shows the 
best results with a highest type 1 error rate of 5.75% compared to 7.95% 
for the logistic regression with robust standard errors and 7.05% for linear 
regression with robust standard errors. Additionally, the Satterthwaite T-
Test had the lowest range of type 1 error rates. Having a consistent range 
is desirable because it allows for more consistent interpretation across the 
range of the data. Also, as can be seen in the non-corrected tests, 
violations of assumptions can also deflate test statistics (Keppel and 
Wickens 2007). This shows up as dramatically lower error rates in this 
simulation. Having error rates as close to 0.05 as possible allows for 
maximal inference within the general linear framework researchers are 
used to.  
Discussion:  
Monte Carlo Simulations are a useful method to ensure the results 
obtained by a given statistical test are accurate and trustworthy; especially 
across the range of large biomedical datasets. While the thousands of 
calculations which must be performed can be computationally intensive 
and time consuming, the use of sampling methods combined with high 
performance computing methods will dramatically reduce the time 
necessary to perform Monte Carlo Simulations. Depending on the number 
of contrasts needed to be run (ie sample size and variance pairs for 
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example) with the aid of high performance computing methods, 
simulations such as the one presented in this chapter can likely be 
perfomed on an average single computer in less than an hour.  
 While there is a cost associated with adding another step to 
standard research protocolsl, researchers should consider the cost in the 
context of a larger research project. At a minimum, excessive type 1 or 
type 2 errors could yield an uninterpretable dataset. However, 
corporations intending on commercializing a product based on 
experimental results could easily lose tens or hundreds of thousands of 
dollars when future testing fails to replicate inaccurate results. So, while 
there may be a small cost associated with performing Monte Carl 
simulations routintely, the cost is likely to be dramatically less than the 
cost of obtaining inaccurate results. 
High Performance Computing Methods:  
In this experiment since the data is randomly generated, there is no 
need to connect to a database because the data is not stored anywhere. 
However, given the thousands of models which need to be estimated, 
multi-core parallel processing and grid distributed processing are highly 
useful for minimizing the processing time necessary to complete such 
simulations.  
There are a number of strategies that can be employed to 
parallelize a Monte Carlo simulation ad described in this chapter. One is to 
divide the thousands of replications within a specific model (ie 
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Satterthwaite T-Test) across multiple cores or machines. A second option 
is to run all of the replications on a single core but stripe the methods 
across cores or machines. For example, all of the runs in a T-Test could 
be run on one core while all of the runs for the Satterthwaite correction 
could be run on a second core. The choice on how to parallelize the task 
is largely process dependent. If a number of complex iterative models are 
being run with a number of simple methods, the simpler methods may 
finish much quicker than the complex iterative methods thus not making 
optimal use of available computing resources.  
Conclusion: 
The results of this simulation suggest that the Satterthwaite T-Test 
is the best and most consistent test given the structure and nature of the 
immunosignaturing data. While it is predictable that the normal theory 
tests would fail, the magnitude with which the someitmes did was not 
predictable. For example, ordinary least squares regression sometimes 
produced type 1 error rates in excess of 50%. Without running this 
simulation, the magnitude of the failure of OLS as well as the fact that 
logistic regression with robust standard errors had a nearly 40% higher 
maximum type 1 error rate than the Satterthwaite test would have been 
impossible to know.  
This simulation is the underlying research which led to the use of 
the Satterthwaite test in chapter 5. Given the complexity and range of 
observations in modern biomedical data it is highly recommended that 
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researchers make use of simulations to ensure the tests they are using 
are giving accurate results not only for a single comparison but across the 
entire range of data in the study. 
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CHAPTER 4 
Multi-level Modeling 
Chapter Overview: 
 This chapter presents the use of multi-level modeling in the real 
world example of modeling adherence to medical treatment. The ways in 
which clustering commonly exists in biomedical data is discussed along 
with the deleterious effects clustering has on model performance by 
violating assumptions of independence of observations. Multi-level 
modeling examples are presented to illustrate how to correct for 
clustering. In the process it is discussed why it is necessary to center 
variables and for researchers to document how they centered in order to 
obtain and accurately interpret multi-level modeling results. Additionally, 
multi-level models estimate new variance parameters. The estimation and 
interpretation of these new parameters is highlighted as a powerful 
method for helping to better understand the complex relationships 
underlying the data.  
Problem Abstract:  
Clustering is a common occurrence in biomedical data that 
dramatically increases its complexity. If left uncorrected, clustering can 
cause a number of problems.  These include parameter estimates that can 
be incorrect in both their sign and magnitude. This often artificially reduces 
the standard errors and thus leads to inflated type 1 error rates. Multi-level 
modeling is a widely accepted method for addressing the problems 
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created by clustering. Unfortunately, multi-level modeling is not as widely 
used in biomedicine as it should be. When multi-level models are used in 
biomedicine they often omit critical pieces of information necessary to fully 
interpret their results, such as how the variance was partitioned.  
 Additionally, beyond simply correcting for a clustering problem, 
multi-level models are also necessary to truly make sense of the 
complexity inherent in the data. Multi-level models provide estimates of a 
number of new parameters, such as variances at multiple levels, which 
allow researchers to answer questions about the complex structure and 
nature of the data that cannot be answered with classical models.  
Methodological Background: 
While T-Tests and classical linear models are highly useful, they 
cannot answer every question. Computer implementations of Maximum 
likelihood and the EM algorithm have given rise to an entirely new set of 
methods in recent years which allow researchers to ask new and 
fundamentally different questions than they could in the past. Although T-
Tests and other generally computationally simple methods are highly 
useful in many situations, given the increased complexity of the data and 
our need to ask more intricate questions, newer more advanced models 
can help researchers extract more information from biomedical datasets.  
As with so many other statistics, the history of multi-level modeling 
can be traced back to R.A. Fisher in his paper, “The Correlation of 
Relatives on the Supposition of Mendelian Inheritance” (R. Fisher 1918). 
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While the mathematical foundations have existed for some time, the use 
of random effect and multi-level models was not highly utilized for years 
because one problem with Fisher’s early work was that the model would 
not work with unbalanced designs. Fisher did also invent maximum 
likelihood but it was the advent of the EM algorithm and computers that 
made the iterative process for estimating general forms of these models 
possible (Goldstein 1986) (Longford 1987).  
Multi-level models started to gain more widespread 
acknowledgement in the mid 1990’s and have become fairly common; 
especially in social sciences and epidemiology. Stulberg et al. 2010 used 
a multi-level model to control for clustering created by taking 
measurements across multiple hospitals and Mills et al. 2006 used multi-
level modeling to account for regional clustering in the sampling design 
across geographic regions (Stulberg, Delaney, et al. 2010) (Mills, et al. 
2006). Wile there are numerous examples of multi-level modeling being 
used in premier journals such as JAMA, there are also examples in which 
no metion of efforts taken to control for possible clustering. Parker et al. 
2009 propose a possible gene signature for breast cancer samples but 
they use samples from two distinct sample types fresh frozen and parrifin 
fixed formalin embedded (FFPE) which come from 5 different cohorts 
(Parker, et al. 2009). Across the many different comparisons performed, 
there is no mention of clustering in the paper. While the probablity does 
exist that the effect was neglegible, this is highly unlikely. Personal 
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research not discussed in detail in this dissertation found that with similar 
breast cancer samples from multiple cohorts exhibited intraclass 
correlations (a measure of clusering) in excess of 0.6 (Seliegman and 
Brown 2011). 
Even though many papers have used multi-level modeling in 
bionmedicine, one error or omission which often exists is in centering the 
variables. Enders and Tofigi 2007 note that even in the social sciences 
where multi-level modeling is heavily used, that “the issue of centering has 
been discussed in the literature, but it is still widely misunderstood” 
(Enders and Tofigi 2007). This is equally valid for biomedical research. 
Neither Stulberg, Delaney, et al. 2010 or Mills, et al. 2006 who take the 
first step and recognize a multi-level model is necessary, make any 
mention of centering; which is critical to obtaining accurate parameter 
estimates in multi-level models.  
In a standard regression model, centering is the process of 
subtracting a constant, often the mean, from all observations (Cohen, et 
al. 2002). This has the result of making the intercept the expected value at 
the mean of the data rater than when x=0 (Cohen, et al. 2002). This 
process only changes the interepretations of the coefficients but in no way 
changes the significance of the model.  
However, in multi-level models, centering is necessary to obtain 
accurate non-biased parameter estimates (Raudenbush and Bryk 2001). 
This is because there is a complex relationship between the independent 
  71 
and dependent variables at two or more levels; the individual unit level of 
observation as well as the grouping or cluster level (Raudenbush and Bryk 
2001) (Enders and Tofigi 2007). This leads to a significant problem 
because, as in standard ordinary least squres regression, the relationship 
between an independent and depenedent variable is captured by a single 
variable.  
The interpreation depends on how the multiple variances are 
partitioned. There are two main types of centering: centering within cluster 
where the cluster mean is subtracted from each observation within a 
cluster or grand mean centering where the grand mean for the entire 
sample is subtracted from each score. Both methods produce dramatically 
different interpretations and parameter estimates. For example, if the 
question of interest is a level 1(or unit of observation level) such as 
number of comorbid conditions a patient has, the recommended approach 
is to center within cluster because this removes all of the variaibility due to 
the level 2 variable or unit of clustering such as the doctor he/she sees or 
the hosptial he/she is admitted to. Grand mean centering the level 1 
variable such as number of comorbid conditions would yield an estimate 
confounded with level 2 or cluster level variability (Enders and Tofigi 
2007). Conversely, if the question of interest was a level 2 cluster level 
variable or a cross level interaction, such whether the effect of number of 
comorbitidies (level 1 unit level observation) of a patient on some outcome 
depends on the number of physician years of experience (level 2 cluster 
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observation), centering within cluster would make it impossible to estimate 
because all of the cluster level variability would be gone. Rather a 
researcher would want to grand mean center in these types of cases. 
Ostensilby, without knowing how, if at all, Stulberg, Delaney, et al. 2010 as 
well as Mills, et al. 2006 centered their variables, it is impossible to 
interpret their model results, parameter estimates and thus conclusions.  
While using multi-level modeling to correct for clustering is a useful 
and necessary procedure, multi-level modeling provides a plethora of 
additional information beyond simply correcting for the structure in the 
data which does not meet certain statistical assumptions. Most authors in 
biomedicine, Stulberg and Mills included do not make use of the additional 
information and estimates provided generated when running a multi-level 
modeling. One example of the utility of this which is presented is that this 
approach allows researchers the ability to estimate the relative amount of 
variability in adherence to medical treatment for doctors and patients 
separately. Multi-level modeling is generally underutilized in biomedicine 
and when it is, it is almost exclusively used to correct for clustering rather 
than using the additional complexity to help better explain the world 
around us. 
The following section which investigates adherence to treatment 
illustrates not only the classical use of multi-level modeling for correcting 
for clustering within the data but also demonstrates how additional 
sources of information in the model such as the new variance estimates 
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can be very useful in helping untangle the complexity underlying 
adherence to treatment. 
Experimental Study Background:  
Adherence to standards of care has been studied for decades 
across a variety of populations and settings with mixed results. Patient’s 
characteristics (age, sex, ethnicity, marital status) are important in some 
studies but not in others (DiMatteo, et al. 2002) (Vermeire, et al. 2001) 
(Martin, et al. 2005). The differences among the studies may reflect 
unobserved interactions between patient characteristics and different 
health conditions, omitted effects such as insurance coverage and 
geographic differences in practice, or may be simply the artifacts of 
different methods.  
Case studies find that patient – physician communication is an 
important influence on adherence. The odds of a patient adhering have 
been found to be 2.16 times greater if his or her physician is a good 
communicator (Zolnierek and & DiMatteo 2009) (DiMatteo, et al. 2002) 
(Vermeire, et al. 2001). The advantages of the communication studies are, 
however, achieved at the cost of limiting inferences to small groups of 
physicians and patients, often in experimental settings. The results 
presented here are complementary, gathering information on day to day 
care in non-experimental settings for large numbers of physicians and 
patients.  
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We use a large, community wide, multi-payer data set to estimate 
the extent to which variations in adherence rates among patients within 
each of 17 groups of health conditions reflect differences in the patient-
constant characteristics of primary care physicians or physician-constant 
differences among their patients. The community is Maricopa County, 
Arizona which includes Phoenix, the sixth largest city in the United States. 
The focus on one county, albeit a very large area, minimizes geographic 
variations in customary care. The data are a subset of the data supplied 
by three commercial insurers, namely: Cigna, Humana and Health Net of 
Arizona; and the Arizona Medicaid (AHCCCS) system as part of the 
Phoenix Healthcare Values Measurement Initiative (PHVMI) (Johnson, et 
al. 2011).  The complete data set include rates of adherence to more than 
300 guidelines, 58 health conditions and 38 million claims for 918,370 
patients.  The analysis data include 52,895 patients, 17 chronic conditions 
and 3,037 primary care physicians who treated the patients. The 17 
conditions, which are described in Table 3, are illnesses for which 
adherence to recommended care can yield significant benefits. Primary 
care physicians were selected rather than specialists because we assume 
that PCPs are more likely to have ongoing contacts with their patients.  
Table 3 List of Conditions Studied 
Condition 
Diabetes Care (NS) 
CAD (NS) 
Asthma (NS) 
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Cholesterol Management (NS) 
CHF (NS) 
DMARD Therapy in RA (NS) 
ADHD (NS) 
LBP Imaging (NS) 
Pharyngitis (NS) 
URI (NS) 
Bronchitis, Acute (NS) 
Depression Med Management (NS) 
COPD (NS) 
Cardiac Surgery (NS) 
Alcohol Treatment (NS) 
Emergency Medicine (NS) 
COPD Exacerbation (NS) 
 
Adherence has been defined as the “active, voluntary, and 
collaborative involvement of the patient in a mutually acceptable course of 
behavior to produce a therapeutic result”. (Meichenbaum & Turk, 1987)  
The comparison of a large number of standards of care for a large 
population requires a complex array of assumptions and procedures. We 
selected Symmetry EBM Connect® 7.6 as our software of choice. EBM 
Connect®, a product of the Ingenix Corporation, identifies gaps between 
clinical evidence and health care practice with applications for a variety of 
health care organizations. (Ingenix, Inc., 2008)  EBM Connect® compares 
actual, observed patient care with care indicated by research-based 
guidelines 
Methods: 
A two-level hierarchical model is used to estimate the results.  As in 
previous studies the hierarchical model controls for the effect of clustered 
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variables, namely clustering of patients by physician (Stulberg, Delaney, et 
al. 2010) (Mills, et al. 2006).  Correlations between groups of clustered 
variables reduce variance estimates, leading to inflated test statistics; type 
1 (false positive) errors.   
We are also interested in estimating the extent of clustering to understand 
how much of the variance in adherence rates can be attributed to patients 
versus physicians.  
The model includes two parts, the first of which (level 1) is used to 
estimate the variation in adherence rates among patients, controlling for 
differences among physicians. Level 2 of the model estimates the 
influence of differences among physicians on adherence rates controlling 
for differences among their respective groups of patients. Separate 
estimates are prepared for each of the 17 health conditions.  
Two different specifications of the model are estimated, namely: a model 
without covariates (the random effects model) and the model with 
covariates.  
Adherence rates are known to vary among different conditions but 
the variance in individual adherence rates within a specific condition is not 
well established. We begin our modeling within specific condition groups 
such as asthma and diabetes. We select physicians who see at least 5 
patients for a given condition. The selection process removes outliers, 
providing a more representative estimate of physician level variances. 
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Patients are defined as adherent when 80% or more of rule measures 
were met (Halpern, et al. 2006); (Mallion, et al. 1998); (Lee, et al. 1996). 
Random Effects Multi-Level Model: 
We use multi-level modeling to study adherence. The first step in 
any multi-level model is to assess how much, if any, clustering exists and 
whether or not that amount of clustering warrants the use of a multi-level 
modeling correction. In our model, factors relating to patient adherence 
will comprise the level 1 variables while factors relating to physicians will 
be the level 2 variables. Since patients are nested or clustered within 
physicians, patients seeing the same physician will likely be more similar 
in adherence because of factors such as physician-patient communication 
patterns. Clustering reduces within class error rates because adding one 
additional case to a study does not add one full piece of information as a 
result of the correlation between cases nested within a class.  
In other words, because individuals seeing a similar physician are 
likely to be have at least some correlation, (a degree of similarity) knowing 
something about one patient provides some information about other 
patients and how they are likely to adhere; part of which may be due to 
seeing same physician. Subsequently, this phenomenon known as an 
intra-class correlation reduces the denominator of many regression based 
statistics and thus false positive rates associated with statistical 
hypothesis testing. 
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The first phase of this study is a random effects multi-level model 
as specified by the following set of equations: 
Yij = B0j + rij    Equation 1 
B0j = Y00 + μj                               Equation 2 
where: the outcome variable Yij is a measure of adherence to treatment for 
an individual i in class j. B0j is the mean adherence value for class j and rij 
is the deviation between and individual’s score i and their respective class 
mean j. Y00 measures the grand mean across all groups and μj is the 
deviation between the grand mean and the mean for class j. This notation 
shows level 1 and level 2 equations separately. However, the level 2 
equation can be substituted into the B0j term of the level 1 equation to 
create a combined equation as follows: 
Yij = Y00 + μj + rij   Equation 3 
Equation (3) implies that an individual’s level of adherence can be 
accounted for by the physician/prescriber they see as well as some unique 
individual variance. This model partitions the variance into independent 
orthogonal level 1 and level 2 components. 
 This model can be used to estimate a number of informative 
factors. One is the intra-class correlation (ICC). The ICC measure 
quantifies the effect of level 2 clustering on the data. In other words, the 
ICC provides the expected correlation between two patients’ scores from 
the same level 2 cluster. In this study the ICC measures correlation 
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between the adherence scores of two patients who see the same 
physician. The ICC is calculated as follows: 
ICC= 
   
       
    Equation 4 
 The model also estimates parameters τ00 and σ2. τ00 is the level 2 
variance between class means. This variance estimate is between class 
means because the average value for individual scores i form the input for 
class j at level 2. σ2 is the average within class variance at level 1. Taking 
the square root of the variance estimates τ00 and σ2 will yield standard 
deviations and an estimate of the size of the difference between  an 
individual’s score and  their group mean (the average for others who see 
the same physician, σ2) as well as how much difference there is between 
physicians on mean adherence (τ00). Table 4 shows the ICC, level 1 
variance, level 1 standard deviation, level2 variance and the ICC. Notice in 
table 4 that the square root of the variance estimates give the standard 
deviations. 
From here, assuming we find evidence of clustering and differences 
between physicians, a number of other variables can be added to the 
model. Age, severe comorbidities and type of insurance (public or private) 
can be added as level 1 variables. Physician specialization can be added 
as a level 2 variable. After adding variables to a model, both the level 1 
variance σ2 and the level 2 variance τ00 can be recomputed. The 
recomputed values will tell us how much variance at each level was 
accounted for by adding a given set of predictors. In addition, we can 
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estimate how much variation in level 1 and level 2 is not due to the added 
predictors in our model. 
Figure 1: Multi-Level Modeling Variance Partitioning 
 
In graph 1 represents sample data for the purpose of helping to 
make the multi-level conceptions of variance more clear. In this graph 
individual compliance rates are plotted by different doctors. The thick 
black line is the grand mean or the average compliance rate across all 
patients. The circles identify more clearly patients seeing a single doctor 
and the thin black lines at the center of the circles are the mean 
compliance rate for physicians. The blue lines between the physician 
mean (thin black line in the middle of the circles) to the line at the end of 
the circle is indicating the spread of patient adherence rates. This is the 
variation for patients seeing a single doctor. The average spread or 
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variance across all doctors is the level 1 variance. If there was no level 1 
or individual level variance, there would be no circle and all of the patients 
would have the same adherence rate. The orange line from the physician 
mean to the grand mean represents the level 2 or physician level 
variance.  
Although there are a number of factors relating to individual 
adherence, at a more fundamental level, graph 1 shows that an 
adherence rate for an individual has two components. One part is the 
natural propensity of an individual to adhere due to intrapersonal factors 
such as age, sex, number of times they visit a doctor. The second part is 
the physician they see. Factors such as physician communication and 
experience may serve to shift an individual’s likelihood of adherence up or 
down. The magnitude of this shift can be conceptualized as the overall 
width of the orange lines. As physicians pay a larger effect on an 
individual’s likelihood of adhering, the average width of the orange lines 
(distance between average compliance of all patients a physician sees 
and the grand mean) gets larger. Factors such as physician 
communication patterns and years of experience may influence how their 
patients adhere. Unfortunately because we are using public health data, 
we do not have data on communication patterns. However, we are still 
able to measure the magnitude of the effect that physician level (level 2) 
and individual level (level 1) variables have on the adherence rates of 
individuals.  
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Results Random Effects Multi-level Model: 
Table 4 represents the findings from the random effects multi-level 
model. We will start by considering diabetes as an example to illustrate 
the interpretation of the results. For coronary artery disease (CAD), τ00 
has a value of 0.006148 and is the level 2 variance which quantifies 
between cluster (physician variability). The standard deviation for the τ00 
(square root of the variance) at level 2 (within physician) is approximately 
7.8% (0.07841). In other words, the mean compliance rate of patients 
being treated by a given physician for CAD should over repeated sampling 
on average range between 40.96% and 71.7% (95% confidence interval). 
Within each cluster (physician) the variance (level 1 variance / sigma 
squared) is 0.0951. This says that within each cluster (physician) an 
individual patients compliance will on average differ from that doctors 
mean compliance by approximately 30.84% (note the square root of a 
variance is a standard error and the √       = .3084). 
Is what this illustrates is that the within class variation is much 
greater than the between class variation or that there is much more 
variation between individual patients seeing a physician than there is 
between the average compliance rates across physicians. Said differently, 
in the case of diabetes, although the physician bears some responsibility, 
individuals are far more responsible for adherence; or lack thereof than 
physicians.  
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An ICC of .05 is often used to determine whether or not there is a 
significant effect of clustering. Having an ICC greater than .05 suggests 
that there is a significant effect of physician or that adherence differs 
significantly based on which physician an individual goes to.  
By looking at the ICC and variance components across multiple conditions 
(Table 4) a number of interesting trends emerge. First, the level 1 or 
individual level variance is always much larger than the level 2 or 
physician level variance. This suggests that like with CAD, factors relating 
to the individual seem to be a larger driving force behind adherence than 
factors associated with the physician. The level 1 variances also replicates 
the findings from previous research showing that individual adherence 
differs across condition.  
As with the level 1 variances, the level 2 variances differ across 
condition. Interestingly, the level 2 physician level variances and ICC’s 
suggest that difference among physicians in the treatment of conditions 
such as coronary artery disease, ADHD, cardiac surgery and depression 
medication management physicians, have little effect on adherence rates. 
With ICC’s less than .05 in these conditions, variations in adherence rates 
among patients account for such a disproportionately large amount of 
variance, that the role of the physician is negligible; if even existent.  
In the case of ADHD, this makes some intuitive sense. This is because a 
primary treatment for ADHD today is amphetamine based stimulants. 
Drugs such as Adderall and Ritalin are controlled substances for which 
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there are very strict treatment guidelines. As a result, it would be unlikely 
to see large differences between physicians. In the case of cardiac 
surgery, since heart related conditions are among the leading causes of 
death in America, there is substantial amount of literature and emphasis 
on best practices for treatment. Therefore, like with ADHD, the message 
physicians are giving their patients is not likely to vary too much.  
However, depression medication is interesting because in many respects 
it is exactly the opposite of ADHD and coronary artery disease because 
best practice treatment guidelines are not well defined. Perceptions about 
treatment and the theoretical construct of depression likely varies a 
significant amount among both physician and individuals. It is initially 
unclear as to why there is almost no discernible difference at the physician 
level. One hypothesis might be that because the individual level variance 
is large, the physician level variance has little room to play any role. The 
problem with this hypothesis is that DMARD therapy also has a large 
individual level variance while simultaneously having one of the largest 
physician level variances. Furthermore, the physician level variance for 
ADHD is ostensibly zero. There are other conditions such Pharyngitis and 
COPD in which the physician level plays a large role. Understanding the 
causal factors underlying why the physician level variances differ so 
precipitously across condition is a novel question for future research.  
Table 4 Physician Level Variances 
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Condition Level 2 
Variance 
Level 1 
Variance 
Level 2 
Standard 
Deviation 
Level 1 
Standard 
Deviation 
ICC 
Diabetes Care (NS) 0.002875 0.02666 0.05362 0.16327 0.09737 
CAD (NS) 0.006148 0.0951 0.07841 0.30838 0.06072 
Asthma (NS) 0.002845 0.1008 0.05334 0.31752 0.02745 
Cholesterol 
Management (NS) 
0.004328 0.02941 0.06579 0.1715 0.12828 
CHF (NS) 0.08466 0.1422 0.29096 0.3771 0.37318 
DMARD Therapy in 
RA (NS) 
0.04707 0.1992 0.21695 0.44631 0.19113 
ADHD (NS) >.0001 0.2344 >.0001 0.48412 >.0001 
LBP Imaging (NS) 0.007291 0.1678 0.08539 0.40961 0.04165 
Pharyngitis (NS) 0.085 0.142 0.29154 0.37678 0.3745 
URI (NS) 0.04487 0.1141 0.21184 0.33772 0.28235 
Bronchitis, Acute 
(NS) 
0.01069 0.1943 0.10339 0.44078 0.05215 
Depression Med 
Management (NS) 
>.0001 0.2018 >.0001 0.44921 >.0001 
COPD (NS) 0.05198 0.1742 0.228 0.41733 0.22987 
Cardiac Surgery 
(NS) 
0.003214 0.06865 0.05669 0.26201 0.04472 
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Alcohol Treatment 
(NS) 
0.03799 0.05936 0.1949 0.24363 0.39023 
Emergency Medicine 
(NS) 
0.03544 0.08143 0.18827 0.28536 0.30327 
COPD Exacerbation 
(NS) 
0.03156 0.1298 0.17766 0.36033 0.19556 
 Beyond the ICC which tells us which conditions have significant 
clustering, the interesting and noteworthy finding is that while physician’s 
do bear some level of responsibility for lack of adherence, the patients 
always account for a greater proportion of variability. This finding would 
not have been possible with simpler models such as a t-test or standard 
ordinary least squares regression. This is because neither model allows 
researchers to estimate the parameters necessary to partition the variance 
between patients and physicians in an interpretable fashion. The next 
section shows how multi-level models can be used with covariates to 
understand predictor variables which help explain adherence to treatment. 
Additionally, the section demonstrates proper centering of variables to 
obtain accurate and un-confounded parameter estimates.  
Multi-Level Model with Covariates: 
A random effect multi-level model is a starting place to determine 
the feasibility of further exploring more complex multi-level models. For 
example, one reason for not continuing to build a more complex model is if 
random effect results do not show a significant ICC or level 2 variance 
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component. This is because if there is no intra-class correlation and 
significant level 2 variance component then there is no need or validity to 
using a multi-level model. As a result, a subset of conditions were selected 
for further analyses.  
The variables explored were public versus private insurance 
(insurer type), gender, age, number of patient visits, ethnicity and 
physician years of experience. Physician experience was centered at the 
grand mean while patient age and number of patient visits were centered 
within cluster in order to give an unbiased estimate of the level 1 or 
individual level effect. Centering patient age or number of patient visits at 
the grand mean would confound the estimates with level 2 variability. 
Physician experience was centered at the grand mean because it is a 
level 2 variable predicting physician mean adherence and therefore 
centering within cluster is not an option. Insurer type, gender and ethnicity 
were dummy coded. For insurer type, private was coded zero, for gender 
male was coded zero and for ethnicity Caucasian was always coded zero. 
In a dummy coded model, the regression coefficients represent the 
expected change in the mean from the group coded zero to the group 
coded 1. For example, if there was a positive coefficient for a gender 
dummy code, this would mean that on average, females are expected 
comply more than males by a given amount. The model estimated is as 
follows: 
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Yij = Y00 + Y01(physican years experience cgm) + Y10(patient age 
cwc)  + Y20(number of visits cwc) + Y30(patient gender) + Y40(insurer) + 
Y50(Asian) + Y60(Black) + Y70(Hispanic) + Y80(Native American) + 
Y90(Other) + U0j +rij   Equation 5 
Or 
Yij = B0j + Y10(patient age cwc)  + Y20(number of visits cwc) + 
Y30(patient gender) + Y40(insurer) + Y50(Asian) + Y60(Black) + 
Y70(Hispanic) + Y80(Native American) + Y90(Other)  +rij 
B0j = Y00 + Y01(physican years experience cgm) + U0j  Equation 6 
Y00 is the grand mean, Y01, Y10 – Y90 are regression coefficients 
U0j are random slope for level 2 and rij is the level 1 residual. Patient age, 
number of visits and gender are level 1 variables while physician years of 
experience is a level 2 variable. The results of the multi-level models do at 
some point find a significant effect for all of the variables. However, 
variables are not significant across all conditions. Furthermore, the effect 
size and trend is equally inconsistent. A Bonferroni correction was made 
for alpha inflation or multiple testing and our nominal alpha or p-value for 
significance was set at 0.005. This was done because with p=.05, by 
chance alone 1 out of 20 tests would be significant. Since we had 10 
variables we were testing 10 variables per condition, we reduced the 
alpha level or nominal p-value for significance to keep the probability of a 
type 1 error or false positive what it would have been if we only ran one 
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test for one condition. Table 5 shows the statistically significant factors 
after this correction factor was made. 
Table 5 Significant Predictors 
Description Effect Estimate Standard 
Error 
Degrees 
 of 
Freedom 
T-
Value 
P-
Value 
Alcohol 
Treatment (NS) 
Gender  -0.04814 0.01043 2411 -4.61 <.0001 
CAD (NS) Gender  -0.04927 0.007967 6021 -6.18 <.0001 
Cholesterol 
Mgmt (NS) 
Gender  -0.01838 0.004686 6371 -3.92 <.0001 
COPD 
Exacerbation 
(NS) 
Gender  0.06915 0.01607 2576 4.3 <.0001 
CAD (NS) Insurance 
Type 
-0.1204 0.01026 2141 -
11.73 
<.0001 
COPD 
Exacerbation 
(NS) 
Insurance 
Type 
-0.3468 0.02915 2574 -11.9 <.0001 
Diabetes Care 
(NS) 
Insurance 
Type 
-0.02175 0.002145 5.30E+04 -
10.14 
<.0001 
CAD (NS) Patient Age -0.00444 0.000306 5860 - <.0001 
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14.53 
Cholesterol 
Mgmt (NS) 
Patient Age -0.00216 0.000204 6294 -
10.57 
<.0001 
COPD 
Exacerbation 
(NS) 
Patient Age -0.01226 0.000778 2552 -
15.75 
<.0001 
Diabetes Care 
(NS) 
Patient Age 0.000923 0.000045 7.50E+04 20.57 <.0001 
DMARD 
Therapy in RA 
(NS) 
Patient Age -0.00709 0.001354 638 -5.24 <.0001 
Alcohol 
Treatment (NS) 
Number of 
Visits CW 
0.01069 0.002016 2348 5.3 <.0001 
CAD (NS) Number of 
Visits CWC 
0.01905 0.002953 5792 6.45 <.0001 
COPD 
Exacerbation 
(NS) 
Number of 
Visits CWC 
-0.00952 0.002106 2535 -4.52 <.0001 
Diabetes Care 
(NS) 
Number of 
Visits CWC 
0.00223 0.000175 7.50E+04 12.71 <.0001 
LBP Imaging 
(NS) 
Number of 
Visits CWC 
-0.1867 0.01751 2317 -
10.66 
<.0001 
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COPD 
Exacerbation 
(NS) 
Hispanic 1.0194 0.08615 2559 11.83 <.0001 
Diabetes Care 
(NS) 
Hispanic 0.09725 0.0119 7.50E+04 8.17 <.0001 
Diabetes Care 
(NS) 
Native 
American  
-0.078 0.003468 7.40E+04 -
22.49 
<.0001 
Diabetes Care 
(NS) 
Other 
Ethnicity 
0.006962 0.00139 7.50E+04 5.01 <.0001 
URI (NS) Years 
Practiced 
GMC 
-0.0032 0.000741 187 -4.32 <.0001 
Diabetes Care 
(NS) 
Asian -0.01431 0.00505 7.60E+04 -2.83 0.0046 
CAD (NS) Hispanic -0.1812 0.0622 5995 -2.91 0.0036 
Alcohol 
Treatment (NS) 
Native 
American  
-0.09684 0.02878 2402 -3.36 0.0008 
Alcohol 
Treatment (NS) 
Years 
Practiced 
GMC 
-0.00263 0.000742 195 -3.54 0.0005 
Cholesterol 
Mgmt (NS) 
Insurance 
Type 
-0.02726 0.007537 5339 -3.62 0.0003 
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Bronchitis, 
Acute (NS) 
Patient Age 0.003572 0.00099 1655 3.61 0.0003 
A number of more complex models with higher order terms, such 
as quadratic trends, interactions, cross level interactions and additional 
random slopes were studied. However, trying to force more exotic model 
specification onto all conditions led to problems such as non-convergence 
need a highly tailored model specification for each individual condition to 
yield meaningful results.  As a result of the highly specific nature of each 
model, such results are not readily comparable across conditions and are 
not presented.  
Results Multi-Level Model with Covariates: 
Beyond the global trends and partitioning variance in adherence 
between patients and physicians, our models provide a wealth of 
information about how common covariates differ across condition. Age is 
the single most prevalent influence on adherence rates. Age significantly 
influences adherence rates for 9 of the 17 conditions studied.  The effect 
of age on adherence rates is similar to the other significant influences in 
that it is positive or negative, depending on the health condition being 
considered. An additional year of age, all else equal, increases adherence 
rates among patients with diabetes, ADHD and Bronchitis but reduces 
adherence rates among patients with CAD, Asthma, Cholesterol 
Management, DMARD therapy, COPD and COPD Exacerbation.  
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Statistical significance tests indicate that an effect is not random, but very 
small effects can be statistically significant. It is useful, therefore, to also 
consider the size of the significant effects. The effect sizes associated with 
age are generally small, ranging from -0.1 percentage points to +3.7. 
Except for the maximum estimate (+3.7) which applies to a very restricted 
age range, the estimates would increase substantially if applied to the 
multi-year age groups typically used in research on health or health care.  
Being female has a significant influence on 5 of the 17 health conditions 
with the direction (positive or negative) varying among different conditions. 
All else equal, female patients are less adherent than males if they are 
being treated for CAD, Acute Bronchitis or problems with Alcohol. The 
estimates range from -2.5 to -4.1 percentage points relative to the 
adherence rates, all else equal, of males with the same conditions.  
Females are likely to be more adherent than males if the criteria refer to 
avoidance of imaging for acute low back pain or appropriate treatment for 
COPD Exacerbation. The estimates are 3.9 percentage points for lower 
back pain imaging and 6.3 percentage points for COPD.  
The effects of ethnicity are not uniform among the health 
conditions. Being Hispanic is a significant influence on adherence for only 
2 of the 17 conditions, namely diabetes or COPD exacerbation. Hispanic 
(H) patients with diabetes are, all else equal, more likely to be adherent 
than White, Non-Hispanic patients (WNH), but Native American (NA)  
patients are less likely to be adherent than either Hispanics or White Non-
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Hispanic (WNH) patients with diabetes. Hispanic patients, all else equal, 
have adherence rates that are 3.7 percentage points higher than those of 
WNH. NA patients have rates that are 7.3 percentage points lower than 
those of WNH. The only significant effect of being NA, other than for 
diabetes, is for patients with upper respiratory infections, and the effect is 
positive rather than the negative effect for diabetes. Adherence rates for 
NA URI patients are 9.9 percentage points higher than for WNH patients.  
The variations among different diseases in direction, significance 
and size of the association between patients’ characteristics and 
adherence rates echoes the lack of agreement in previous research 
studies concerning the importance of demographics on adherence rates 
(cited in the Background section of this portion of the report). Our results 
show that demographic characteristics have a significant effect on 
adherence, but those relationships are very different for different 
conditions.  
The remaining results refer to one measure of public versus 
commercial insurance coverage and two measures of physician 
characteristics. The results for insurers do not allow for interactions 
between insurer type and adherence rates. That would require estimating 
separate results for each type of insurer which was beyond the scope of 
this part of the report. The inclusion of a one-zero variable in which public 
insurer=1 captures shifts in the intercept of the equation, but not 
interactions between insurer type and all the other variables in the model.  
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There is no significant difference between coverage by public versus 
commercial insurance for 13 of the 17 health conditions. The exceptions 
are for CAD, Cholesterol Management, COPD Exacerbation and Diabetes 
for which adherence rates are, in each case, reduced if, all else equal, a 
patient is covered by public insurance. The estimates range from -3.9 
percentage points for Cholesterol Management to -18.1 percentage points 
for COPD Exacerbation. The results for public insurance may include a 
selection bias since persons with mental health problems are more likely 
to be on public insurance.  
Two variables, namely years in practice and number of visits for 
each patient seen by a physician were included in the model to provide 
some controls for differences among physicians. The interpretation of the 
association between years of practice and adherence rates, controlling for 
patient characteristics, is straight forward. The effect of number of visits is, 
however, subject to uncertainty concerning causal direction, although it 
does indicate the extent of contact between a physician and a patient. We 
will, therefore, restrict our discussion of the results to the years of practice 
variable and treat the visits variable as a pure control.  
An additional year of practice by a physician is significantly associated, all 
else equal, with differences in adherence rates for only 3 of the 17 
conditions, namely: CAD, URI, and Alcohol Treatment. The effect of a 
single year is quite small, less than one to three tenths of one percent, 
indicating that substantial differences only occur over ten to twenty year 
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differences in physician practices. Thus, one expects the large differences 
to exist between relatively young physicians and physicians in their sixties 
or older.    
Discussion: 
Adherence to treatment has been studied in numerous different 
contexts across a plethora of settings. Our study takes a slightly different 
approach in that we ask the question of how much of the variance in 
adherence is due to physician related factors and how much is due to 
patient factors. Our use of hierarchical (multi-level) modeling to partition 
variance between groups in clustered datasets is by no means technically 
new. However, this method is less commonly used in the study of 
adherence. Stemming from past literature, in a second set of analyses we 
also look at the role of previously identified factors relating to adherence. 
While in the first part of our study, hierarchical (multi-level) modeling was 
used as a tool to partition variance, in the second part modeling factors on 
adherence, the use of this method is necessary to obtain statistically valid 
estimates. This is because clustering in datasets, if not correct for through 
methods such as hierarchical (multi-level) modeling will lead to 
dramatically inflated type 1 error rates (Raudenbush and Bryk 2001). 
In contrast, many studies tend to focus more on the specific factors 
relating to adherence. For example, McKinlay et al. examine sources of 
variation in physician adherence with clinical guidelines and Cabana et al. 
similarly study why physicians do not follow clinical practice guidelines. In 
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acknowledgement of the fact that physicians often do not follow 
guidelines, the New England Health Care Institute conducted a study to 
identify barriers and develop strategies for improving physician adherence 
to clinical guidelines. The New England Health Care Institute identifies the 
medical payment system, IT infrastructure, physician culture and the 
current guideline development process as barriers to physician adherence 
to guidelines. The Institutes report also identifies a number of potential 
interventions to improving physician adherence to guidelines. Although we 
do not explicitly test many of these things such as IT infrastructure or 
medical payments, we believe that many of these factors would be 
subsumed within the physician variance component. This is because to 
the extent that IT infrastructure or medical payments are a factor, 
differences in adherence related to them would show up in different mean 
adherence rates between physicians. While these may be important 
factors which show statistically significant results in studies on their own, 
our research suggests that the overall magnitude of their effect in the 
broader context of adherence is likely small because physician related 
factors globally contribute to a small fraction of the variance in adherence 
rates. We believe that interventions focusing more on patient centric 
aspects of adherence would be a better use of finite resources.  
In addition to physician factors on adherence, a vast literature spanning 
decades exists examining patient factors relating to adherence. Dimatteo 
et al. and Vermeire et al. both provide excellent meta-analyses and 
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reviews of the literature regarding patient factors on adherence (DiMatteo, 
et al. 2002) (Vermeire, et al. 2001). Our study, like many meta-analyses 
does not find a clear and consistent effect for many demographic variables 
such as age, gender, race or even physician years of experience on 
adherence. Dimatteo et al. and Richard et al. examine the effects of 
patient non-adherence in health outcomes. Choudhry, Fletcher and 
Soumerai find that physicians with more years of experience are 
sometimes at risk for providing lower quality care and may need quality 
improvement interventions (Choudhry, Fletcher and Soumeral 2005). We 
find that in 3 of the 17 conditions studied, physician years of experience is 
correlated with decreased adherence rates. Although we only observe this 
in a small subset of conditions, it is tangentially consistent with the general 
findings of physician performance degradation over time.  
Many researchers have noted that adherence is also likely a factor 
of the interaction between physicians and patients (Zolnierek and & 
DiMatteo 2009).  Zolnierek & DiMateo specifically conduct an extensive 
meta-analysis regarding the effects of physician patient communication on 
adherence. Decades of research identifies a number of factors on both the 
patient and physicians sides of adherence as well as factors relating to the 
interaction between patients and physicians. Our contribution is that we 
are able to show that while there is clearly a non-ignorable portion of 
variance associated with adherence is due to physicians, in every 
condition we studied, a much larger portion can be attributed to the 
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patients. Given the consistency of the finding that more variance can be 
attributed to patients than physicians in all 17 conditions studied, we 
suggest placing more emphasis on focusing interventions more on 
patients than on physicians. While physicians are an easier group to reach 
for interventions, without a strong intervention that produces large effects, 
in the bigger picture of overall adherence, such programs may not have 
the largest overall impact.  
The characteristics included in the model (insurance type, age, 
gender, ethnicity and number of visits, years of practice) account for some 
of the variance in adherence rates but the amount of overall variance 
explained is low. In the full models, a pseudo r-squared calculation to 
measure the proportion reduction in variance never reaches the threshold 
for even a medium or moderate effect size for the individual level variables 
tested. The results, calculated for each condition, reflect the fact that much 
of the difference in adherence rates is determined by the type of condition 
being treated rather than variations among patients with the condition or 
among the physicians who are treating them. 
Adherence rates, within type of condition are influenced in greater 
part by differences among patients than by differences among physicians, 
recognizing that our measures of physician characteristics are limited. 
Many conditions exist where a specific physician does have a noticeable 
effect, but even in those circumstances the physician does not appear to 
be the predominant influence.  
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High Performance Computing Methods: 
The Center for Health Information Research stores archival data in 
a SAS database. As a result the analytic program is natively connect to 
the analytic program and eliminates the need for database connectivity 
programs. Nonetheless, the same inherent benefits are realized in that the 
redundant write to disks and increased size of excess output flat files is 
minimized. 
 Multi-level models are iterative models which utilize maximum 
likelihood and the EM algorithm. Given the complexity of the data these 
models sometimes take a large amount of time and number of iterations to 
converge on a solution. Since the model is iterative each run cannot be 
parallelized but each different condition can be. Parallel processing was 
used in a dual core fashion to run the 17 conditions in parallel thus 
substantially reducing the necessary processing time.  
Conclusion:  
 This chapter demonstrates the effective use of multi-level modeling. 
Proper use of the model and centering is illustrated along with how new 
parameter estimates such as level 1 and level 2 variances can be used to 
address the complexity in modern biomedical datasets. Without using 
multi-level modeling the parameter estimates from the model would have 
been dramatically inflated and the researcher would have likely made 
incorrect conclusions about the relationship of many variables.  
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Additionally, without the use of multi-level modeling it would not 
have been possible to partition the complexly tangled variability in 
adherence to treatment accurately between patients and physicians. This 
result gives significant insight into a decades old question and suggests 
that more resources should be allocated to interventions targeted at 
patients to increase adherence to treatment.  
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CHAPTER 5 
Structural Equation Modeling 
Chapter Overview: 
 This chapter presents the use of structural equation modeling to 
better address the complexity associated with the presence of unobserved 
latent variables in a research project. This is illustrated through the real 
world example of an immunosignaturing study to develop diagnostic tests 
to screen for breast cancer. The first section shows that while classical 
tests such as a t-test provide useful information, they are very limited in 
their ability to fully address the complexity inherent in the data and have 
no ability to model underlying latent constructs. The second section 
expands by show how structural equation modeling can be used to better 
make sense of complex data and directly model latent constructs (in this 
case antibodies). Additionally, it is shown how not only can we make 
inferences about the existence of latent constructs but it is also possible to 
model their relationship to other variables such as how they predict 
disease outcomes. This chapter also discusses how the measurement 
model portion of a structural equation model may be used as a diagnostic 
tool for medical devices.  
Problem Abstract: 
One final complexity in biomedical datasets is the presence of 
latent factors where the outcome of interest is not measured directly but 
rather via a number of proxy observations. This occurs commonly in 
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microarray technologies where single nucleotide polymorphisms are used 
to represent the effect of an entire gene, single messenger RNA 
fragments are used to study the expression of an entire gene  or peptides 
are used to study the effects immune response and antibodies. Simple 
statistical models are only capable of studying the marker variables and 
have no way to make any inferences about the larger underlying latent or 
unobserved construct. Structural equation modeling is specifically 
designed to help answer questions about hypothesized but unobserved 
latent constructs. Additionally, beyond investigating the presence of latent 
factors, structural equation models are capable of estimating much more 
complex models in which hypothesized latent factors are treated as 
unique variables to help understand their relationship in the broader 
context of the research study.  
 It is demonstrated how structural equation modeling can make 
sense of complex datasets even when the outcome of interest is not 
directly measured. Applications for diagnostic screening using latent 
factors are also presented.  
Methodological Background: 
 Structural equation modeling is commonly used in the social 
sciences today is comparatively underutilized in biomedical data analysis. 
Despite the relative underutilization of structural equation modeling in 
Biomedicine today, the historical roots can be traced back to work by the 
noted population geneticist Sewall Wright’s work on path analysis. In his 
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1921 paper entitled Correlation and Causation, Wright lays out a 
covariance modeling approach to path analysis as a method for studying 
plant and animal biology (Wright 1921). Path analysis is the basic 
foundation for the structural portion of structural equation modeling 
models. Later, measurement models based largely off of factor analytic 
methods were added to what has become the modern day structural 
equation modeling framework (Bollen, Structural Equations with Latent 
Variables 1989). 
Structural equation modeling provides a robust modeling 
frameworks that is applicable across a wide range of biomedical data from 
genomic and proteomic to public health data. Both Dahly and Yu-Kang 
argue that structural equation modeling is underutilized in many 
biomedical fields; especially epidemiology (Tu 2009) (Dahly, Adair and 
Bollen 2009). The general structure of structural equation modeling makes 
it well suited to addressing many analytic challenges across a wide range 
of biomedical domains. This is because structural equation modeling 
allows users to specify anything from a t-test or simple linear regression to 
highly complex models with latent factor variables and multiple covariance 
structures (Bollen, Structural Equations with Latent Variables 1989). The 
structural equation modeling framework also provides many useful 
attributes for estimation of missing data problems (Enders, Applied 
Missing Data Analysis 2010). 
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Tu suggests that part of the underutilization of structural equation 
modeling in biomedicine may be related to a lack of familiarity with the 
models and the need to learn how to specify more complex models that 
structural equation modeling is capable of addressing (Tu 2009). There 
are examples of structural equation modeling in biomedicine though such 
as the study by Dahly, Adair and Bollen which investigate blood pressure 
(Dahly, Adair and Bollen 2009). Given that Kenneth Bollen is a premier 
researcher on SEM, this in part explains the reason for this study.  
In genetics, most of the structural equation modeling based 
literature focuses on older data and research designs such as twin and 
adoption studies. These studies also tend to focus on psychological 
questions and psychology is a field where structural equation modeling is 
commonplace. Bartels, Cacioppo, Hudziak and Boomsma were interested 
in studying genetic and environmental contributions to stability in 
loneliness throughout childhood while D'Onofrio, Hulle, Waldman, 
Rodgers, Harden, Rathouz and Lahey studied how genetic and 
environmental factors interact with smoking during pregnancy to create 
externalizing problems in children (Bartels, et al. 2008) (D'Onofrio, et al. 
2008). The use of structural equation models in biomedicine, especially 
genetics and proteomics is limited to a specific set of questions usually 
related to psychological outcomes. Structural equation modeling has also 
not made a real forte into mainstream analysis of high throughput 
microarray technologies either.  
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This chapter on statistical methods for analyzing immunosignatures 
provides a number of examples in which the structural equation modeling 
framework can be useful for helping to model complex relationships 
among peptide microarray data. It also presents a model for using 
confirmatory factor analyses or structural equation measurement models 
as a method for screening new samples for disease. It is also 
demonstrated that while simpler classical tests such as T-Tests are useful, 
the same level of information is not able to be obtained without using more 
complex modeling approaches such as those within the structural 
equation modeling framework. Structural equation modeling is necessary 
to untangle the complexity in modern biomedical data. 
Experimental Study Background: 
The human immune system is a rich source of information about 
the health and disease status of an individual (Johnson and Stafford 2009) 
(Metchnikoff and Binnie 2009) (Litman, Cannon and Dishaw 2005) 
(Legutki, et al. 2010).  Immunosignaturing is a new technology that may 
be useful to decode the vast amounts of health information contained in 
the immune system. An immunosignature is a pattern containing 
multiplexed signals from chronic or recently matured antibodies.  These 
signals come from a sufficiently diverse set of peptide targets on a 
microarray.  Thousands of peptides of random sequence (mimotopes) 
provide the density and diversity sufficient to discriminate different 
diseases.  An initial question, and the aim of this chapter, is how best to 
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analyze and decode the information from immunosignaturing studies.  
Previous reports (Legutki, et al. 2010) (Johnson and Stafford 2009) used 
frequentist statistics (ANOVA or t-test) and cluster analysis (hierarchical 
clustering and Principal Components) to identify features that classify 
disease states.  We examine other methods that may yield better 
performance in immunosignature analyses. Corrected T-Tests as well as 
logistic and multinomial logistic regression models have demonstrated an 
ability to differentiate between patients with different disease states even 
after stringent corrections for running multiple statistical tests (alpha 
inflation). Confirmatory factor analysis is an additional method which 
provides an abundance of information relating to the clustering of samples 
as well as providing an alternative method for categorizing and 
determining the disease state of a single sample. Descriptive statistics 
help to paint a better picture of the overall immune system activity. Finally, 
structural equation modeling and mixture models can help explain the 
underlying structure of an immunosignature.  
For these analyses we examined a dataset containing breast 
cancer samples along with patients who had a second primary tumor (not 
a recurrence).  The group with a second primary tumor was included in the 
analyses because if these patients could be diagnosed as having a high 
probability of developing a second tumor, they could be more closely 
monitored.  
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 In an immunosignaturing study, sera samples are collected from 
participants and the physical information from the immune system is 
extracted using high density peptide microarrays. Each microarray 
contains a large number of peptides; in this case 10,375 peptides. The 
selection of these peptides was designed to give broad spectrum 
coverage of relevant antigens in the human immune system. The relevant 
nature of each peptide capitalized on early phage display research 
(Johnson and Stafford 2009). The decision was made to use a peptide 
microarray instead of phage library panning because of the increased 
speed and efficiency offered by a peptide microarray (Johnson and 
Stafford 2009).  Ideally, if we can better understand the information 
captured by the peptide microarrays we may be able to develop quick, 
accurate, unobtrusive and inexpensive screening tests for many types of 
disease.   
 Classic peptide microarrays are created by spotting overlapping 
peptides corresponding to linear sequences of proteins known to be 
involved in an infectious disease.  These arrays cannot identify non-linear 
epitopes.  The epitopes are identified when B-cells produce antibodies 
(usually IgG) specific to 8-12 residue peptides that are components of the 
antigen protein. In contrast, immunosignaturing arrays utilize random-
sequence peptides.  Random sequence peptides have some specific and 
reproducible affinity to antibodies, and determining the level and pattern of 
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binding is core to determining the difference between patients with 
different diseases.  
 Although much research has been done on statistical analyses 
using microarrays, immunosignaturing microarrays pose a number of 
novel challenges not encountered in traditional microarrays. In nucleic 
acid microarray technologies, binding is essentially only between two 
types of molecules of complementary sequence. For example, in a 
genotype array, genomic DNA binds to complementary nucleic acid 
probes that have either matches (e.g., perfect match, PM) or mismatches 
(MM) and the signals from the different probes are combined to make 
homozygous and heterozygous base calls for individual single nucleotide 
polymorphisms (SNPs). In a gene expression microarray, only a specific 
fragment of RNA will bind to the oligonucleotide on the array. With modern 
microarrays, as long as there is a sufficient abundance of RNA on the 
array, it will generally bind only to the specific complementary probe, with 
very limited non-specific binding. 
 With immunosignaturing microarrays, the intensity values are a 
continuous value from 0-65,000 and binding is not restricted to a single 
“complementary” molecule. Multiple antibodies in IgG could bind to the 
same 20mer peptide on the array. Also, although the immunosignaturing 
arrays are designed to measure IgG, there may still be competitive binding 
from other material in the sera and from other types of immunoglobulin. 
Competitive binding could result in an IgG antibody not binding at all or 
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binding with a lower affinity. This could be potentially problematic if the 
auxiliary particle reducing binding affinity does not differ systematically 
across groups. Furthermore, a single antibody may also bind to multiple 
peptides on the array; a problem almost non-existent in genotype or gene 
expression arrays.  
 With the potential for so many different things to bind to a peptide 
on the array, it is not immediately clear how accurately traditional and 
more novel statistical methods would perform. One primary goal of the 
research reported here was to determine if the proposed statistical 
methods were capable of effectively analyzing the data and producing a 
correct pattern of results. For example, with a number of different things 
binding to a peptide and antibodies binding to multiple peptides it was 
initially uncertain if this would produce erratic signatures which would lead 
to incorrect results when certain methods were used.  
 Despite a number of new complexities created by 
immunosignaturing microarrays, these challenges give us the opportunity 
to test the performance of classically used methods such as factor 
analysis models in a different environment while also allowing us to ask 
new and fundamentally different research questions. In order to answer 
these new research questions, there is a need to use different statistical 
models not commonly used to analyze microarray data. This is because 
more traditional models used to analyze microarrays lack the versatility to 
adequately capture and explain the complexities of immunosignatures. 
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Here, we explore the use of structural equation models in order to try to 
determine whether the immunosignature formed by the fluorescent values 
of the 10,375 peptides is mostly random or if there is a consistent 
underlying pattern or factor structure to an immunosignature that 
correlated with disease. This research question is made possible because 
of the novelty in immunosignaturing arrays that that allow a single 
antibody to bind to multiple peptides on the array. This research shows 
that there are complex and consistently reproducible structures underlying 
peptides which differentiate groups. Such patterns can be used as 
biosignatures for disease as well as provide deep insight into antibodies 
and immune response to disease. Although there are new analytic 
challenges in immunosignaturing, it is these exact challenges that provide 
the promise of new discoveries while laying the groundwork for 
applications in future research and technologies.  
 In this chapter we present a range of statistical methods, their use 
and demonstrate what type of information they can provide researchers in 
immunosignaturing studies. We show the ability to classify samples into 
their respective disease categories and find peptides which significantly 
predict disease status. This provides a promising method for screening 
and potentially presymptomatic screening of disease. We also identify a 
number of latent factors using structural equation modeling. We 
hypothesize that the latent factors being modeled may represent specific 
antibodies that differ among disease classes.  
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Methods: 
 Patient samples are analyzed by applying the sera or plasma to the 
array at a 1:500 dilution, detected with an anti-human fluorescent 
antibody, and the signals are read using an Agilent C laser scanner.  
Images are processed using GenePix Pro 8 providing a text file of values 
for each peptide.  Binding affinity is a continuous value from 0-65,500 (16 
bit image). Genepix software was used to convert the 16-bit TIFF images 
to values, median non-background subtracted values were used and log10 
transformation was done on the median normalized intensity values. 
Three distinct datasets were used in these analyses. One was a set of 
samples from a random group of individuals without breast cancer, a 
second set of samples is from a group with breast cancer and finally the 
third set of samples is from a group of patients who were diagnosed with a 
second primary tumor. The normal samples were a convenient sample of 
individuals without any known breast cancer history. The breast cancer 
samples were a sample of current breast cancer patients with different 
levels of disease progression and diverse demographic backgrounds. 
There were 52 samples from normal individuals without cancer, 98 
samples from cancer patients with a single primary tumor and there were 
21 samples with second primary tumors. Human subjects protection was 
observed, collaborators ensured all samples were collected under the 
same protocol. All of the samples came from females between the age of 
45 and 54. The specific participant age for each sample was kept from us 
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because of HIPPA and patient privacy concerns. All pre-processing was 
median-normalization per microarray slide, to adjust for global intensity 
bias. Data was also log10 transformed.  The spot intensity was the median 
signal (obtained by GenePix Pro) with no local background 
subtraction.  Background subtraction was not used because the arrays 
showed consistent background across the 1172 empty spots which were 
spread across the physical surface of the array.  Technical replicates also 
showed greater reproducibility without background subtraction than with, 
indicating that the method for subtracting background was not useful.  
Additionally, the local and global background estimates were, on average, 
150-300 RFU, which for any microarray is extremely low considering the 
3+ logs of dynamic range. 
 It is common in similar lines of research, such as genotype 
experimentation to use a pattern matched experimental design. Matching 
participants in an experiment has the effect of increasing homogeneity 
among groups. As a result, the reduced within class variation which often 
accompanies matching designs has the effect of reducing the standard 
error and denominator of common statistical tests. This in turn leads to 
higher statistical power. Additionally, more homogeneous groups often 
enable easier classification in exploratory models. In the data analyzed 
here, the normal non-cancer samples were not matched to either the 
cancer groups, however research has shown that the signature of immune 
response is far less susceptible to the type of personal factors that genetic 
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studies are – even HLA has only a minor effect on the consistency of a 
disease state immunosignature pattern (Johnson and Stafford 2009) 
(Legutki, et al. 2010).   
Given that immunosignaturing is a new technology, early 
investigations, contrary to initial belief actually capitalize on the lack of 
rigid experimental designs. This is because additional sources of variance 
in the data allow us to better understand the robustness of the technology 
and related statistical analyses. If a method can perform well in a 
somewhat noisy environment with loose experimental designs, it is highly 
likely to perform even better when well curated studies (such as matched 
designs) are performed. In many respects, testing immunosignaturing data 
with loosely structured and curated data provides a much more stringent 
test of the technology and methods. Being able to obtain statistically 
significant results with the correct patterns of results from such 
unstructured data illustrates the versatility of immunosignaturing 
technology and the statistical methods tested here.  
Understanding the robustness of the technology provide guidance 
for future experiments using this technology while giving insight into the 
potential clinical use of immunosignaturing. Biologically, it is possible that 
healthy normal individuals with no active infection are responding 
immunologically to their environment, and persons with an infection have 
a focused immune response.  It is likely that high variation in immune 
response to an environment would be present across individuals. 
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Therefore, in order to be clinically useful, it is imperative that the 
technology and methods are robust enough to function accurately outside 
of precisely controlled laboratory settings; as would be encountered during 
clinical deployment of the technology. 
Descriptive Statistics: 
The first set of methods presented illustrate the capabilities and 
limitations of classical models such as descriptive statistics, the T-Test 
and factor analytic models. Table 6 provides basic descriptive 
fluorescence intensity statistics of each of the three disease groups.  
Descriptive statistics of an immunosignature provide a significant amount 
of insight into the underlying immune response during disease states. Of 
particular biological interest in this sample is the difference in the range of 
values from the three groups. The normal and single tumor cancer 
samples have ostensibly the same floor value while the second primary 
tumor cancer samples have a much lower floor value. This may suggest a 
suppression of the immune system in second primary tumor cancer 
samples. The single tumor cancer and second primary tumor cancer 
samples have progressively higher maximum values which may suggest 
an increased immune response associated with cancer and a 
reoccurrence of cancer. 
Table 6 Fluorescence intensity and descriptive statistics for the three 
disease groups 
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Group Mean Minimum Maximum Std. 
Deviation 
Variance Range 
Normal 329 207 9672 93 10336 9465 
Single 
Tumor 
336 204 16702 115 16258 16498 
Second 
Tumor 
676 36 49880 549 339301 49844 
 Although there are large differences in the ranges, in order to have 
any predictive validity, the differences in ranges need to be consistent 
across samples within each group. For example, a high fluorescence 
value over 45000 in the second tumor samples needs to occur on a given 
peptide with regularity to produce a statistically significant result.  
Classical Statistical Significance Tests: 
 There are a number of statistical tests which could potentially be 
used to test whether the differences between groups across peptides are 
significant beyond what would be expected by chance alone. Some of 
these methods include the T-Test, corrected T-Tests, Logistic Regression 
and Multinomial Logistic regression. The standard T-Test divides the 
mean difference between two groups by a standard error to produce a T-
Statistic used for null hypothesis significance testing. One problem with 
the standard T-Test is that the test makes the assumptions that the 
variances in both groups are equal. The problem of unequal variances in a 
T-Test is commonly known in the statistics literature as the Behrens-
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Fisher problem and has been researched for the better part of the last 
century in various contexts.  If the assumption of equal variances is 
violated, the T-Statistic can be either inflated or deflated depending on the 
samples sizes in each group. As a result, the analyses were conducted 
using a Satterthwaite corrected T-Test. The Satterthwaite test is one of 
numerous corrections for unequal variances that have been proposed 
over the years. The Satterthwaite test works by adjusting the degrees of 
freedom in the test. The resulting correction produces an asymptotically 
correct T-statistic when groups have unequal variances. The Satterthwaite 
correction works by modifying the degrees of freedom via equation 1: 
( 1 2)*2
 
1*2 2*2
2 1 2 1
w w
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         Equation 7 
A Satterthwaite corrected T-Test and a number of similar test 
corrections which could have also been used such as a Brown-Forsythe 
correction in an ANOVA model tended to produce statistically significant 
results after a Bonferroni correction for multiple testing (alpha inflation). A 
Bonferroni correction was used to protect against alpha inflation because 
with a standard alpha level of .05, purely by chance alone, 1 out of 20 
tests will be significant. The Bonferroni correction divides the alpha value 
by the number of tests run; in this case 10,375, or one for each peptide on 
the microarray. This resulted in a corrected p-value threshold of 4.819*10-
6. Nonetheless, despite this much lower p-value, highly significant results 
are still obtained for Satterthwaite corrected T-Tests comparing normal 
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versus single tumor cancer samples, normal versus second diagnosis 
samples and single tumor cancer versus second primary tumor cancer 
samples. Table 7 shows the top 10 significant peptides for a Satterthwaite 
corrected T-Test comparing normal samples to cancer samples. Logistic 
and Multinomial logistic regression may also be of interest and an 
alternative method for comparing groups to the tests used here. One place 
in which logit models may be useful is if a researcher in future studies has 
a known set of covariates they wish to control for. For example, in the 
study of diabetes, it may be of interest to control for body mass index or 
HB1AC test results.  
Table 7 Top 10 significant peptides for a Satterthwaite corrected T-Test 
comparing normal samples to cancer samples 
Variable 
ID 
Peptide Sequence T-Value DF P-Value 
 
V2833 HFRKWHKRRWKHHKKWKGSC -6.51 132.4 1.4372E-
09  
V3113 HRFKWHWKHRFHHFHRFGSC -6.29 144.4
1 
3.5843E-
09  
V6772 QKFKHQQGSFKLPWLSMGSC -6.29 144.8
4 
3.5843E-
09  
V9732 WRRSTPVGPWTWFGKFLGSC -6.12 146.1 8.1933E-
09  
V7196 RFGRPQHQHDFRRHAIYGSC -6.06 146.8 1.1046E-
08  
V6978 QSHMTLAPGIRRYKKFNGSC -6.06 146.3
2 
1.1046E-
08  
V7387 RMGFGLYERLWGKTNHYGSC -6.01 134.2
6 
1.6532E-
08  
V9561 WKWKRHWKWPHRRKHFFGSC -5.95 144.4
9 
1.9475E-
08  
V6987 QSIGLGYSAFMPKWPFRGSC -5.93 140.1
3 
2.2543E-
08  
V3249 HWKRHHRPKHKHHRHKHGSC -5.9 145.4 2.4586E-  
  119 
08 
Exploratory Factor Analysis: 
 Factor analytic models have previously been used in analyzing 
immunosignatures and are quite common in analyzing high dimensionality 
microarray data (Legutki, et al. 2010) (Kustra, Shioda and Zhu 2006) 
(Blume 2010). Each of the models explored during this line of research 
were investigated in order to determine its feasibility for answering a 
specific research question. Exploratory factor analysis (EFA) was 
examined as a method to be able to differentiate samples based on 
disease states with no prior clinical knowledge of the samples. Estimation 
of EFA models was performed using ordinary least squares (OLS). EFA 
with Promax rotation proved significantly better than chance at classifying 
samples. EFA is a set of procedures that accounts for the relationship 
among a set of variables in terms of a smaller set of underlying latent 
constructs or factors. (For example, a factor is a disease state.) We 
specifically use principal axis factoring with iterated communalities. 
Although PCA and EFA are quite similar, an important difference between 
the two methods is that PCA makes the assumption that all of the variance 
in an item is a reflection of common variance shared among all items 
whereas EFA posits that each item shares some common variance with all 
other items but also has its own unique variance. Mathematically the 
difference between PCA and EFA is the addition of single matrix; D2. 
Rzz = A * Rf * A’ + D2        Equation 8 
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In equation 2 Rzz is the correlation matrix among the observed variables. A 
is a matrix of factor loadings, Rf is the correlation matrix among the factor 
loadings, the A’ denotes the transpose of the A matrix of factor loadings 
and thus ARfA’ is the matrix representation of the common factor 
structure. D2 is a diagonal matrix that captures the unique variance 
weights and distinguishes EFA from PCA.  
 Varimax and Promax rotation methods were explored in depth. This 
is in part because Varimax is often a starting point for a Promax rotation. A 
sample is said to “load on” a given factor when the model suggests a 
strong fit on the given factor. Rotation in EFA is a method for making 
factor loadings more interpretable. Rotation methods change the 
relationship between items and the factors (which are geometrically 
represented as axes). Rotation does not change the relationship among 
the individual items. Since rotation methods only make changes to the 
axes and not to the communalities (variance accounted for), rotation does 
not mathematically change the initially obtained results. Rotation makes 
the factor loadings more interpretable. 
 Varimax uses a complexity function to maximize the variance of the 
squared loadings on each factor. This results in loadings with a more even 
spread across the factors; as opposed to having an overabundance of 
loadings on a first factor. Varimax is an orthogonal rotation that maintains 
the orthogonal (90 degrees) intersection of the axes. This has the result of 
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keeping the correlation between the factors at zero because the cosine of 
90 degrees is 0. 
 Promax is an oblique rotation that allows the angle between the 
axes to vary. In statistics, variance has to be accounted for in some part of 
the model. Allowing the axes to vary and thus a correlation between the 
factors is another path to account for variance. Allowing variance to be 
expressed in terms of correlations between factors has the result of not 
forcing variance between factors to be represented as between item 
variance. This can result in cleaner factor loadings. Additionally, the 
assumption that there is no correlation between factors, or in this analysis, 
disease states, is unlikely because there will always be some additional 
common variance and similarities in immune samples due to basic 
immune responses and structures present across all samples.  
 Unlike Varimax, Promax does not use a complexity function. 
Rather, Promax rotation is a procrustean rotation to a target matrix. In 
Promax, a pattern matrix of loadings (often derived from Varimax rotation) 
is taken to some power (i.e., squared, cubed etc.) to form a target matrix. 
The original loading components are then rotated to get as close as 
possible to the newly formed target matrix.   
A number of EFA models with Promax rotation were run to 
investigate the utility of this method for differentiating between groups with 
no prior knowledge of group membership. Table 8 provides summary 
results. The number of factors was known to be 2 for each comparison. 
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Scree plots were used to validate the hypothesis. None of the plots 
suggested the presence of a strong third factor. A scree plot plots the 
eigenvalues for each component. The largest components before a 
leveling off is used to determine the appropriate number of factors. Factor 
loadings greater than .3 were said to load on a given factor. If loadings for 
both factors were less than .3 the sample was said to not counted as a 
correct classification on either match. Catell (1966) provides a more 
detailed description of how to use eigenvalues and scree plots for 
determining the number of factors (Cattell 1966). 
Table 8 Exploratory Factor Analysis Results 
 EFA Model Correct Classification 
Single Primary Tumor and Second Primary 
Tumor Samples 
93.45% 
Non-Cancerous and Second Time Cancer 
Samples 
84.4% 
Non-Cancerous and First Time Cancer Samples 68% 
 
 An EFA between cancer samples and the samples from patients 
who had a second primary tumor produced a correct classification for 
93.45% of the cases. Of the cases that were miscategorized, all of them 
except one were cancer cases that loaded more highly with the second 
primary tumor group. There are a few possible explanations for this. This 
could simply be model error resulting from the lack of homogeneity among 
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the first time cancer group. However, it is possible that the miscategorized 
cases may represent individuals who will at some point in the future 
develop a second primary tumor or are unbeknownst to the researchers 
already in the process of developing one. All this says is that less than 
10% of cancer samples are more closely related to the samples of 
individuals who had acquired a second primary tumor than the samples 
with a single primary tumor. 
 A second EFA was run between the normal or noncancerous 
samples and the samples with a second primary tumor. The overall 
classification accuracy was 84.8%. Within this model, 74.1% of the normal 
samples loaded correctly on the same factor whereas 100% of the second 
primary tumor samples loaded on the correct and same factor. 
 A third EFA was run exploring the relationship between normal or 
non-cancerous samples and single tumor cancer samples. Using the 
same model specifications as in the first model, this EFA produced a 68% 
classification accuracy. Although this is quite low by traditional model 
building standards, there are a number of factors relating to the data which 
may make this a useful starting point. First, the normal patients were taken 
from a wide range of convenient lab samples. Some of the normal 
samples may have come from individuals outside of the age and 
traditional demographic background to even be remotely at risk for breast 
cancer. Secondly, the stage and progression of cancer patients was 
unknown. As a result, an additional possibility for the classification 
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accuracy may be that the cross loadings represent a mixture of early 
stage cancer patients and those at high risk for or who are developing 
cancer.  
 Unfortunately, detailed information about the disease state of the 
samples is unavailable and thus makes any conjecture purely 
hypothetical. However, in all models, the results are significantly better 
than chance and illustrate in many ways the performance of the 
technology and approach under adverse conditions. The three models 
taken in concert illustrate that the lack of a concrete and well curated 
control group is likely responsible for the decremented classification 
accuracy in some models. This can be most clearly seen when 
considering that the single tumor cancer and second primary tumor cancer 
samples consistently exhibit stable factor loadings with relatively low cross 
loadings because the single tumor cancer samples serve as a much 
cleaner control group for the second primary tumor cancer samples than 
the normal do for either of the cancer groups. This early research 
suggests that future studies using more precisely selected control groups 
and experimental design would have even better ability to classify cancer 
patents. 
 Beyond classification accuracy, the similarity between different 
factor based models and rotations is extremely informative from a 
biological perspective. All combinations of PCA and EFA with Varimax or 
Promax gave highly similar results with respect to overall classification of 
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groups across a number of different analyses. Although specific factor 
loadings certainly had different values, the overall picture and 
classification accuracy was relatively constant. Brief investigations into 
other rotations such as Oblimin were also explored in the context of EFA 
models and produced similar results to Varimax and Promax.  
 First, with respect to PCA versus EFA, the lack of difference 
suggests that the vast majority of the variance accounting for classification 
is at the factor level (ie. ostensibly disease state) and not the individual 
level.  This is because as the D2 matrix which differentiates the two 
methods captures the unique variance in an EFA model and as the D2 
matrix approaches zero, an EFA model approaches a PCA model. 
Therefore, since the D2 matrix is the only difference in the equation and an 
analytic solutions exists due to Ordinary Least Squares estimation, we can 
conclude that the lack of difference was because there was relatively little 
unique variance present.  
Confirmatory Factor Analysis: 
 Since EFA models showed the ability to differentiate samples, a 
logical clinical application of immunosignaturing would be to screen a 
single sample from an individual to determine his or her disease status. 
Confirmatory factor analysis (CFA) was chosen as an ideal method for 
investigating this question due in part to the similarity with EFA and 
because of the versatility to examine one specific sample in detail. EFA is 
an exploratory method that should be used when the number of groups or 
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structure of the data is not well understood. Conversely, CFA is a 
confirmatory method that can be used when the structure of the data is 
well understood. As the name implies, exploratory factor analysis, EFA 
models should not be used as confirmatory model or to confirm a 
hypothesis. 
 Both CFA and EFA attempt to explain the underlying structure in a 
dataset. However, CFA and EFA approach the problem from two distinct 
directions. EFA makes almost no prior assumptions about the structure of 
the data and attempts to sort through the data to help a researcher 
determine what the underlying structure of the data is. In this research, the 
general group membership was known and thus the appropriate number 
of factors was specified apriori. In a CFA model, the researcher explicitly 
identifies not only the number of factors but which cases load on each 
factor as well as factor variances, covariance’s between the factors and 
disturbances for each item. CFA models are not data mining approaches 
and require well formulated notions about the underlying structure of the 
data.  
 Mathematically, the simplest formulation of a CFA model in matrix 
notation is: 
X = Λ * ξ * ΔL      Equation 9 
In Equation 3, X is a vector of observed variables, Λ is a matrix of factor 
loadings, ξ is a matrix of scores for each variable on a factor or latent 
construct and Δ is a vector containing measurement error.  
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In the CFA models analyzed here, one sample from each factor 
(disease state) was chosen at random as a scaling constraint in order to 
ensure identification in these models. Maximum likelihood estimation with 
robust standard errors was used to estimate these CFA models. The 
known disease status was the basis for defining the factor loading for each 
sample. A sample was allowed to load only on a single factor and fixed to 
zero on the other. Variances and covariance’s between all factors were 
estimated. Summary results are provided in Table 9. 
Table 9 Confirmatory Factor Analysis Results 
CFA Model Correct 
Classification 
Single Primary Tumor and Second Primary Tumor 
Samples 
89.9% 
Non-Cancerous and Second Time Cancer Samples 93.1% 
Non-Cancerous and First Time Cancer Samples 83.4% 
For a CFA comparing single tumor cancer samples and second 
primary tumor samples, 89.9% of samples loaded on the specified factor. 
For a normal versus second primary tumor CFA, 93.1% of the samples 
loaded on the specified factor and a normal versus single tumor CFA 
produced sample loadings on the specified factor 83.4% of the time. The 
difference in classification accuracy between the CFA and EFA models is 
due to a number of factors; some of which include model variance and 
covariance specifications as well as different estimator types.  
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One primary advantage CFA models have over EFA models are fit 
indices which give some quantitative measure of how accurately the 
specified model is. Although there are a plethora of fit indices that have 
been proposed within the structural modeling framework that CFA models 
reside, the chi-square difference test, root mean square error (RMSEA) 
and standardized root mean error (SRMR) are among the most common 
and widely cited. 
The chi-square test ostensibly tests how well the specified model 
reproduces the covariance matrix from the original data. The problem with 
this test is that it is so sensitive that it is nearly impossible to obtain 
statistically non-significant results. It is important to note that the null 
hypothesis of this test is that there is no difference between the specified 
model’s covariance matrix and the covariance model in the actual data, a 
non-significant p-value is the desired outcome. Because it is of interest to 
find no difference between the specified model and the data, a non-
significant p-value is the goal. The chi-square test for all of the CFA 
models was significant with p<.001 suggesting that there is a statistically 
significant difference between the specified model covariance matrix and 
the covariance matrix of the original data. However, the chi-square test is 
extremely sensitive and often detects trivial differences [8-9]. Noting the 
sensitivity of the test is not meant to suggest that in fact the specified CFA 
models are perfect fits or deny lack of fit. Rather, the test is noted because 
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it is among the most common fit indices and the issues with the test are 
noted as a means of providing appropriate context for the results. 
The Root Mean Square Error of Approximation (RMSEA) and the 
Standardized Root Mean Square Residual (SRMR) are two common fit 
indices used in the Structural Equation Modeling framework description; of 
which CFA is a part of. The basis of the RMSEA is a non-centrality 
parameter. The simplest reduced form of the RMSEA equation is: 
RMSEA = 
2
1
1
x
df
n
 
 
 

      Equation 10 
In equation 4,    is the model generated chi-square value, df is the 
degrees of freedom and n is the sample size. Smaller RMSEA values 
suggest better fit. The SRMR measures the standardized difference 
between the observed covariance matrix and the model implied 
covariance matrix.  
For the CFA model for single tumor samples versus second primary 
tumor samples, the RMESA was .083 and the SRMR was .071. For the 
CFA model comparing normal versus second primary tumor samples the 
RMSEA was .097 and the SRMR was .076 while the normal versus single 
tumor samples produced a RMSEA of .07 and a SRMR of .074. These are 
marginally significant results because traditional benchmarks cite .05 as a 
cutoff for statistical significance (Bollen 1993). RMSEA and SRMR values 
in the .05-.08 range are usually regarded as marginally significant. 
Although the results do not meet the rigid .05 level, they are actually quite 
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impressive when considering the experimental design and the fact that a 
portion of the lack of fit may actually be representing natural biological 
patterns such as the development of a first or second tumor. 
Perhaps the real utility of a CFA model for immunosignaturing could 
come in the form of diagnostic testing. Given the accuracy of the CFA 
model with this data, once a well curated set of samples for a certain 
disease or collection of diseases has been established, a CFA model 
could be specified where a new unknown sample could be allowed to load 
on both (or multiple) factors. By comparing the relative loadings on the 
factors, it would be possible to determine to which group the sample most 
likely belongs. For example, there are numerous subtypes of breast 
cancer and different stages of disease progression. If a collection of 
samples was available as a concrete reference set, a CFA model could be 
easily and accurately employed as a new method for aiding in the 
diagnosis as well as perhaps early detection of breast cancer. 
Structural Equation Models: 
While the method presented above are highly useful, they are 
inherently limited in the amount of complexity they can unravel. Structural 
equation modeling helps us better understand the complex underlying 
nature of immunosignatures. From EFA, CFA and descriptive statistics we 
know that the immunosignatures as a whole are in fact different across 
groups while corrected T-Tests show that there are statistically significant 
systematic variations. The logical question arising from these findings is 
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how precisely do the immunosignatures differ from one another? Is there a 
clear, consistent and reproducible pattern underlying the differences in 
immunosignatures across disease states? Because a single antibody can 
bind to multiple peptides and different antibodies can bind to the same 
peptide, a coherent pattern of peptide fluorescence across an 
immunosignature is much more informative than the fluorescence of 
individual peptides on their own. Furthermore, being able to identify 
common relationships and covariances between groups of peptides is of 
even greater utility. This can be accomplished by modeling latent factors. 
On a genotype microarray, the probe is directly measuring an 
individual’s genotype at a specific location. In contrast, the peptide probes 
on an immunosignature array are indirectly measuring immune response 
and antibodies present in the sera. When measures are not directly 
observed they are often referred to in statistical and structural equation 
modeling literature as latent factors. If there are clear, consistent and 
reproducible patterns caused by specific antibodies in a sera sample 
binding to peptides on an immunosignaturing array, it should be possible 
to model individual antibodies as latent factors. For example, when 
reading the tick marks on a mercury thermometer, one is not reading a 
direct measure of temperature but rather displacement of mercury. The 
latent factor measured by displacement of mercury is temperature 
because from a purely physics standpoint, temperature is the kinetic 
energy of an object; usually measured at the molecular level. Another 
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example of a latent factor is depression. Psychologists cannot directly 
measure depression but they can ask a series of questions that 
cumulatively allow them to model the latent construct of depression. Each 
question in a depression inventory gets at one small piece of the latent 
factor depression in much the same way that peptides on an 
immunosignaturing array provide an indirect measure of immune 
response; as measured primarily by IgG antibodies.  
Structural equation modeling is specifically designed for modeling 
latent variables. Structural equation modeling models have two parts: a 
path model comprised of regressing a set of variables on another and a 
measurement model in which CFA is used to form latent variables. When 
a set of measured variables is set to load on a given factor, the result is a 
latent factor. In structural equation models, the resulting latent variables 
can be treated as either endogenous or exogenous variables; depending 
on the research question of interest. A full structural equation model is a 
collection of equations defining each variable and their relation to one 
another. Since complex models can quickly generate a large number of 
equations, structural equation models are often represented graphically for 
quicker interpretation. Since confirmatory factor analysis is a major 
component in a full latent variable structural equation model, attempting to 
classify samples with factor analytic methods lent evidence to the 
feasibility structural equation models. These early models also provided a 
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plethora of background information which aided in the testing of full 
structural equation models.  
Initial Structural Equation Modeling Testing: 
Despite evidence from previous factor analytic models that 
structural equation models should be feasible, since these are highly 
complex models, an incremental approach was taken to building and 
testing large structural equation models. To start with, a measurement 
model and full structural equation model was run using the top three 
peptides from the normal versus single tumor cancer samples (Table 7) to 
predict disease. The measurement model (ostensibly a confirmatory factor 
analysis) in a structural equation model tests the loadings of individual 
peptides onto latent variables.  In this model one peptide was set as a 
scaling constraint and the other two were freely estimated. Three peptides 
were chosen because that is the minimum needed for model identification 
and provides for the simplest model. Because of the iterative nature of the 
maximum likelihood algorithms used structural equation models, starting 
with a simple model reduces computational time and aids in convergence. 
Furthermore, starting with the simplest model and building up is good 
practice in modeling. 
 Since a measurement model with 3 factors is just identified or has 
no extra degrees of freedom, fit indices cannot be calculated. However, all 
the variables load strongly on the latent factor with loadings greater than 
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.7. This finding suggests that the top 3 peptides are indicative of a single 
underlying latent factor.  
In order to help rule out the possibility that the consistent loadings 
in the first model were not type 1 error or false positive, the same model 
specification was run in an attempt to see if the top 3 peptides 
differentiating single tumor cancer samples from second primary tumor 
cancer samples. In this model the top 3 peptides also loaded on a single 
latent variable. Like the first model, the second model illustrated the same 
pattern of results with the top 3 peptides all significantly loading on a 
single latent factor. 
The same pattern of results can be replicated with two disease 
contrasts. Replicating the finding with normal versus a single primary 
tumor cancer and second primary tumor cancer versus single primary 
tumor dramatically reduces threats to validity against causal conclusions 
proposed by structural equation models of immunosignaturing data. 
When investigating models that differentiate two distinct groups 
from a baseline group (in this case single tumor cancer samples) there are 
three potential outcomes. First, a complete lack of model fit and no 
consistent underlying factor structure. In this case, none of the peptides 
would load consistently and correctly on either of two specified factors 
suggesting that peptide florescence is random. The second possibility is 
that all of the peptides would load on one factor. This result could result 
from any number of potential biases in the technology itself, printing or 
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processing of the microarrays. Another reason all of the peptides might 
load on one common factor is that they are all part of a single latent factor. 
However, because the significance of each peptide varies quite 
precipitously across group contrasts, it seems unlikely that a single 
underlying latent factor would produce different significance values across 
disease contrasts. The third possibility is that the peptides significantly 
load on two separate factors and that the peptides for each contrast 
exhibit no cross loadings. 
A series of analyses was run using significant peptides from normal 
versus single tumor cancer corrected T-Tests as well as second primary 
tumor samples versus single tumor samples combined into a single 
model. The first model was a measurement model which added the first 
two CFA’s into one model. The top 3 peptides for normal versus single 
tumor samples and single tumor samples versus second tumor samples 
each were set to load on a separate latent factor.  A covariance between 
the two latent variables was also estimated. The path diagram in Figure 2 
illustrates this model. In Figure 2’s path diagram, the square boxes 
represent measured variables, which, in this case are peptide fluorescent 
values. The large circles are the unmeasured latent variables. The arrows 
between the latent factors and measured variables show which measured 
peptides load on which latent variable. The curved arrow represents an 
estimated covariance between the two latent variables. 
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Figure 2 Latent & Measured Variables in Immunosignaturing
 
 In path diagrams, the arrows represent the causal flow of 
information. The arrows are pointing from the latent variables to the 
measured variables because the argument in structural equation models 
is that there is some unmeasured and underlying latent construct that is 
responsible for the observed results of the measured variables. The 
immune response and antibodies present in the sera samples is the 
ultimate causal factor of peptide fluorescence.  
 The model tested in Figure 2 was estimated using maximum 
likelihood estimation with robust standard errors (MLR). The model 
exhibits excellent model fit with an RMSEA of .063 and an SRMR of .031. 
In addition, the Chi-Square test was not significant, Chi-Sq=14.054, df=8, 
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p=.0804. A non-significant Chi-Square test is the desired result. Again, this 
is because the null hypothesis of this Chi-Square test is that there is no 
difference between the observed covariance matrix (input data) and the 
covariance matrix implied by the model in Figure 2. These results strongly 
suggest excellent model fit and that the latent factors are unique 
constructs. Biologically, this suggests that a different latent factor is 
underlying each latent variable. 
 To further confirm the interpretation that the latent factors are 
different, one peptide from each factor was switched. V3113 and V10218 
were set to load on the opposite factor from the first model. In this new 
model, there was a complete lack of fit. In addition to poor loadings, the fit 
indices dramatically decreased. The RMSEA was .354, the SRMR was 
.192 and the Chi-Square was 198.704, df=8, p<.0001. Thus further 
suggests two different underlying constructs rather than statistical 
anomalies. 
An additional set of analyses were run using the top 5 peptides 
instead of just the top 3. The first models run in this sequence were 
Varimax and Promax exploratory factor analyses. Both models gave 100% 
classification with extremely strong loadings on each factor. Table 10 is 
the rotated factor pattern or a two group EFA taking the top 5 peptides 
from each disease contrast. This clearly illustrates the top five peptides 
strongly load on factor one while the last five strongly load on the second 
factor. The loadings of peptides are consistent with the groups from which 
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each peptide was selected. For example, v4356, v10218, v7869, v8672 
and v8170 were the top 5 most significant peptides differentiating first time 
cancer samples from second time cancer samples. In combination with 
earlier results, this very clear and consistent loading pattern strongly 
suggests that the top peptides for each class form unique latent variables 
and they are almost irrefutably measuring different constructs. Biologically, 
this suggests that the latent factor which is more active in single tumor 
cancer samples compared to normal samples is not the same latent factor 
that appears to be present in second tumor samples. 
Table 10 Rotated factor pattern for two group EFA of significant peptides 
Peptide ID Peptide Sequence Factor1 Factor2 
V4356 KYQFAGQRSGKQYRWRIGSC 0.88773 0.05624 
V10218 YQPPPRKAVIQMDWLSYGSC 0.92126 0.06844 
V7869 SKFRDVLTFNEPSRFVSGSC 0.51657 0.04716 
V8672 TVHESMIYRMRFMTFKHGSC 0.93261 0.04783 
V8170 SWRRMRMHKNFMISNLDGSC 0.87997 0.06368 
V2833 HFRKWHKRRWKHHKKWKGSC 0.11128 0.7436 
V3113 HRFKWHWKHRFHHFHRFGSC 0.06271 0.82673 
V6772 QKFKHQQGSFKLPWLSMGSC 0.12145 0.73203 
V9732 WRRSTPVGPWTWFGKFLGSC 0.05844 0.88795 
V7196 RFGRPQHQHDFRRHAIYGSC 0.035 0.88098 
 The same result was also found by running a two group exploratory 
factor mixture model with Geomin rotation. Geomin rotation is another 
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oblique rotation method similar to Promax. A more complete discussion of 
the mathematical differences of rotation methods can be found in (Browne 
2001). In this data, the observed peptides as a whole form a single 
distribution. In mixture modeling, the underlying notion is that the 
distribution formed by all of the observed data is the product of two or 
more underlying distributions; each of which represents a distinct class. 
Ostensibly, an exploratory factor mixture model is trying to answer the 
same question as PCA and EFA, PAF/Factor Analysis but via a different 
mathematical framework. Despite the complexity of mixture modeling, the 
basis of an exploratory factor mixture model is for a categorical latent 
class variable C, for a specific class k. The model estimated is: 
Yp = Vkp+λkp*η*εp       Equation 11 
In equation 5, for a variable Yp,Vkpis an intercept parameter, λkpis a vector 
of loadings, η is a vector of latent factors and εp is a residual term. In 
addition, there is a correlation matrix Ψk for the latent factors η of class k 
along with a distribution for the latent class variable C: Pk = P(C=K). In this 
equation, for a dependent variable P, the probability of C is equal to k. 
Also, other constraints are added to this basic framework for purposes of 
identification but are related to model specific decisions such as 
orthogonal or oblique rotation. 
 EFA mixture models were estimated using Maximum Likelihood 
with Robust Standard Errors (MLR) estimation and 20 random start 
values. Random starting values were used in part due to the complexity 
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inherent in mixture models and to check for local solutions. By running the 
analysis with multiple random start values log likelihood (LL) values can 
be compared. To the extent that different LL values are obtained, the 
random start values can be directly input into the model and the results 
can be compared to the best fitting LL model. This is useful because if 
different start values produce dramatically different results, this might 
suggest that the algorithm converged at a local maxima instead of a global 
maxima or that the results are unstable. 
 Fit statistics such as the Bayesian Information Criterion (BIC) 
provide a more quantitative analysis of model fit for a series of nested 
models. EFA mixture models were estimated for one, two and three class 
models. This approach allows us to confirm that a two class model is in 
fact the best fit for the data. 
The series of EFA mixture models suggested the same pattern of 
results as traditional EFA models; that there are two distinct and separate 
underlying classes formed by the top 5 peptides for each disease contrast. 
In addition, mixture models also produce a statistic for the average latent 
class probability: 
P ( Yp  =  j | C = K) = φ – 1 ( T *kpj ) – φ – 1 ( T*kpj -1) Equation 12 
In equation 6 T*kpj is a threshold parameter on a standardized correlation 
metric and φ is a matrix of residuals for the latent factors [11]. For both two 
and three class models, the average latent class probability for the most 
likely latent class membership was greater than 99% for both class 1 and 
  141 
class 2. In other words, for the subgroup of samples classified as being 
part of class 1 by the model, more than 99% of the time, class 1 was also 
their most likely class membership. This further reaffirms the excellent 
model classification. The three class model produced nearly identical 
average latent class probability values because the model did not classify 
any of the peptides as belonging to the third class. 
The BIC was used to assess the best fitting model. The BIC is 
estimated as follows: 
BIC = - 2  * LL + p * log(n)            Equation 13 
In equation 7 LL is the log likelihood value of the model, p is the number of 
parameters and n is the number of observations. The lower the value of 
the BIC the better the model fit. Often times, BIC values or plots are used 
ostensibly in the same fashion that scree plots and eigenvalues are used 
in PCA or traditional factor models where a researcher looks for the point 
at which the decrease in values levels off.  However, in this analysis, the 
two class model had the lowest BIC and somewhat unexpectedly, the 
three class model actually saw a slight increase in the BIC This result 
further reaffirms the excellent fit of a two class model. 
As is common in model building, a series of full structural equation 
models were run in increasing levels of complexity. To start with, the two 
latent variables were regressed on their respective disease states in 
individual models. A path diagram for the normal versus single tumor 
samples is presented in figure 3. 
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Figure 3 Path diagram for normal versus cancer peptides SEM model 
 
These models were estimated using MLR. The latent variable 
regression was performed using logistic regression and was significant, 
p<.001. Additionally, the odds ratio was 1.841. This suggests that having 
the attributed measured by the latent variable makes an individual 1.841 
times more likely to develop breast cancer. The same model specification 
for single tumor versus second tumor samples produced similar results 
with p<.001 and an odds ratio of 3.49. In other words, there appears to be 
a latent factor that is present in those who have a single tumor that is not 
present in those samples with a second primary tumor. 
Furthermore, another structural equation model was run combining 
the above two analyses so that the two distinct latent variables were used 
to predict disease status. The estimation of disease status was done via 
multinomial logistic regression. This was done because when the models 
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were combined there were three levels of disease. In a multinomial logistic 
regression model, one level (in this case single tumor samples) was set as 
the reference group. Then n-1 logistic separate regression equations are 
run; where n is the number of levels of the dependent variable. Therefore, 
since each latent variable was regressed on disease status, there were 
two logistic regression equations run. Both latent variables predicted their 
respective disease status with p<.01. Again, this suggests that normal, 
single tumor cancer and second tumor cancer samples are separated by 
different sets of latent variables. 
The first set of structural equation models provided an initial proof 
of concept for full structural equation models. This laid the groundwork for 
the more interesting question of what the underlying structure looks like for 
unique parts of the immunosignatures. Since further investigations are 
meant to look at the overall differences in immunosignatures as a whole, it 
is hypothesized that the latent factors differentiating groups are specific 
antibodies present in the sera samples; as explained above. Two 
experimental tests were conducted: a series of structural equation models 
and an examination of the peptide means across groups. 
Structural Equation Models of Significant Peptides and Antibodies: 
Next, all of the peptides that were statistically significant after a 
Bonferroni correction in the normal versus single tumor and second tumor 
versus single tumor contrasts were selected for further analysis. Following 
the same pattern as before, exploratory factor analysis models were run to 
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determine how many underlying factors appeared to be present. This was 
done because selecting the top peptides might yield more than one factor; 
suggesting more than one antibody. For the normal versus single tumor 
contrast there were 176 peptides that were significant and there were 30 
significant peptides for the second tumor versus single tumor contrast. 
The eigenvalues and scree plots suggest a three factor solution for the 
normal versus single tumor contrast and a one factor solution for the 
second tumor versus single tumor contrast. In other words, for the normal 
versus single tumor, the hypothesis is that there are three antibodies that 
differentiate the groups while there is only a single antibody differentiating 
the second tumor versus single tumor groups.  
 In the second tumor versus single tumor contrast, factor loadings 
from exploratory factor mixture models and Promax EFA models confirm 
an unstable second factor. This is because the loadings on the second 
factor are generally low and minimally larger than the first factor loading 
on the same peptide. Additionally, a two factor solution produced 
Heywood cases in which there were communality estimates greater than 
one; suggesting a problem with the two factor model. When single factor 
models were run, all of the peptides loaded highly on the one factor. As a 
result of the EFA models suggesting a single factor solution, a full 
structural equation model was run in which all of the top 30 peptides were 
set to load on a single latent variable which was then regressed on 
disease status. In this model, the stable latent factor significantly 
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correlated with disease status, p<0.001. The odds ratio of 3.148 suggests 
that the single hypothesized antibody confers significant risk for acquiring 
a second tumor. Also, the means for all of the peptides in the second 
tumor samples were lower than the means for the single tumor samples. 
This suggests immune suppression. In other words, there appears to be 
an antibody present in samples with a single tumor that is not present in 
samples with a second tumor.  
 The normal versus single tumor samples is a bit more complex. A 
full structural equation model containing all three hypothesized factors was 
unable to be estimated because there were more peptides than samples. 
Therefore, there were not enough degrees of freedom to run a full model 
containing all 3 groups. As a result, subsets and individual factors were 
tested individually. When tested individually, all of the three 
factors/hypothesized antibodies significantly correlate with disease, 
p<0.01. Two of the latent factors positively correlated while the third 
negatively correlated with disease status. 
 Within the 176 significant peptides for normal versus single tumor 
samples, 162 peptides increase or have a higher mean in the cancer 
samples than in the normal samples increase. Conversely, 14 decrease or 
have a higher mean in the normal group than in the cancer group. In other 
words, there appears to be two new antibodies present in cancer samples 
not present in normal samples and one antibody present in normal 
samples that is not present in cancer samples. Immunosignatures are 
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unique in analysis of the humoral response in that they can detect 
decreases in reactivity relative to normal levels.  
 One finding of particular note is a high covariance between the two 
positive factors (or proposed antibodies present in cancer that are not in 
normal samples). The high covariance and multicollinearity suggests that 
the two are very similar. When regressing both of the positive latent 
variables on disease, in every instance, only one of the latent factors was 
significant with p<.05. This is likely due to the way in which multiple 
regression partitions variance. In a multivariate regression model, the 
effect of one variable (x) is the unique contribution of that variable with all 
others held constant. Because there is so much common or shared 
variance, a vast majority of the variance is used up or accounted for by the 
first factor, not leaving enough unique unexplained variance left for the 
second factor to be significant as well.  
 A two level measurement model was used to test whether the two 
factors were measuring a similar underlying construct. In this model, the 
two latent factors were set to load on a third latent variable. The reasoning 
behind this test was as follows: if the two latent factors loaded on a single 
second level latent factor, then the two original factors would be 
measuring the same underlying construct. One way this could occur is if 
the antibody had a highly complex structure. This model was not, 
however, statistically significant, RMSEA = .21, SRMR = .09. This 
suggests that the two factors are unique albeit highly similar.  
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 There are a number of potential interpretations of this result. One of 
the more plausible biological hypotheses is the presence of 
subpopulations. Among two different cancer subtypes of single tumor 
breast cancer, there are likely two distinct antibodies; one for each 
subtype. If subpopulations are present in the data, it seems plausible that 
these two antibodies are highly similar because both are, in the end, l 
responding to breast cancer. The variations that lead to different subtypes 
may in fact be what makes the two positive latent factors separate and 
distinct from one another. The multicollinearity may be because they vary 
together, not that they have a similar sequence and see the same antigen.  
If two different antigens consistently arose in a tumor they would raise 
antibodies that varied together in samples but would see completely 
different antigens.  
 A second possibility is that the high multicollinearity is a result of 
modeling different times in the disease progression.  As disease 
progresses it is likely different antigens are presented by the tumor to the 
immune system.  If so, the relative amount of particular marker antibodies 
will also change.   
Implications of Structural Equation Modeling: 
 We have explored a number of statistical models for analyzing 
immunosignatures. Each method explored helps answer a different 
research question relating to the analysis of immunosignatures. 
Descriptive statistics about an immunosignature can provide high level 
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information about the general immune response in a signature. 
Exploratory factor analytic models (PCA and EFA) can be useful for 
classifying immunosignatures into different disease groups without any 
clinical information. CFA models can classify samples onto specified 
factors and could be developed into a useful model of disease. These 
structural equation models identify interesting and robust latent factor 
structures underlying immunosignatures which warrant further 
investigation.  
 Latent factors can be reliably extracted from immunosignatures. 
These latent factors are clear, consistent and replicable patterns which 
differentiate disease states in terms of their statistical significance fashion. 
These latent factors can serve as strong biomarkers for disease. Given 
the design of immunosignaturing and the fact that antibodies are binding 
to peptides on immunosignature arrays, it is highly plausible that the latent 
factors are modeling individual antibodies.  
 Although future research is needed to conclusively confirm the 
relationship between modeled latent factors and antibodies, the potential 
of having a high-throughput bioinformatics-driven method for antibody 
discovery creates countless potential avenues for future applications. The 
primary benefit of this methodological approach is to reduce the time it 
takes to identify antibodies associated with various clinical situations. 
Reducing this time reduces cost and increases the speed of advancement 
in biomedicine. Additionally, the increased speed of analysis and resulting 
  149 
reduced cost may permit applications that were not conceivable just a 
short time ago. For example, a method for quickly and inexpensively 
detecting an antibody could play a crucial first step in developing 
personalized vaccines.  
 Below we present a multi-step procedure for detecting latent factors 
and potentially antibodies in an immunosignaturing study.  The first step is 
to run an exploratory factor analysis on the data with rotation. Various 
rotations should be explored but Promax or Geomin are recommended. 
An EFA model is  a useful starting place for multiple reasons. First, it 
ensures that the groups are different constructs and significantly different 
from one another.  This determination can be made by looking at scree 
plots and eigenvalues to assess the probable number of groups in the 
model; these should be equal to the number of known disease states. The 
samples should load correctly on a given factor with a high classification 
rate.  
 At this point, cross loadings in an EFA model can be investigated. If 
clinical data exists, it would be of use to try to assess whether there are 
potential reasons why a specific sample may be cross loading. For 
example, is there a history of cancer in a normal sample that cross loads 
on a cancer sample which might suggest the person is in a transition 
phase? This may be a way of detecting aberrant cases or outliers. That 
said, haphazardly removing cases from a dataset is NOT advocated. 
Cross loadings were not analyzed in this application due to a lack of 
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additional information and clinical data upon which to draw any relevant 
conclusions.  
 From here, a test of statistical significance comparing the groups 
for the peptides of interest can be done using an appropriate test statistic. 
T-Tests or logistic regression and their multivariate extensions, ANOVA 
and multinomial logistic regression, are a few potential methodological 
tools. The specific test should be picked with respect to the features of the 
data being analyzed. For example, in this chapter, we used a 
Satterthwaite corrected T-Test because of unequal samples sizes and 
variances. The Satterthwaite test was chosen on the basis of the Monte 
Carlo simulation run in chapter 3. A correction should be made to protect 
against alpha inflation. Although a number of tests exist for this purpose, 
the Bonferroni correction is among the most common; even if it may be 
somewhat conservative.  
 A traditional EFA model or an exploratory factor mixture model can 
be used to infer the structure of the significant peptides within each group. 
This information can be used to create a full structural equation model. 
However, as part of good model building practices, starting with a CFA 
measurement model is recommended; especially because the iterative 
nature and complexity of these models may lead to convergence 
problems. Additionally, information from these simpler models can be 
used to specify starting values in full structural equation models if 
convergence problems occur. CFA measurement models specify which 
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peptides load together on a given latent factor. Checking the fit of the 
measurement models can confirm the accuracy of the model. However, 
given that CFA is so similar to EFA methods, it is unlikely that differing 
results would be obtained.  
 Once a working measurement model has been obtained, a full 
structural equation model can be created by regressing the latent factors 
on disease state. It is important to test a full structural equation model for 
a number of reasons. Although EFA and CFA models may suggest that a 
group of significant peptides are related in some way, without a full 
structural equation model, there is no way of knowing whether the 
relationship is a significant predictor of a specific disease state. In the 
absence of predictive validity for a specified disease state, any 
relationship among the peptides is trivial and would not suggest that it is 
because of a common antibody. The same conclusion can made if the 
latent factor is predictive of disease states beyond the hypothesized state. 
 If a significant structural equation model can be obtained, wet lab 
validation can then attempt to determine whether the model is correct. 
One potential way of testing this in the wet lab would be to use the 
designated peptides to affinity purify the antibody from the sera.  The 
prediction is that the different peptides would purify the same antibody.  
This could be tested by immunosignaturing the antibodies purified.   
Screening and Presymptomatic Screening for Disease: 
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The relative ease from which samples can be classified and 
differentiated with all of the methods explored here makes this technology 
an excellent use for disease screening. Whether examining the loadings of 
new samples in a CFA model or as part of a larger structural equation 
model, this technology can allow researchers to screen patients in a 
variety of contexts. This initial research suggests that immunosignaturing 
could be developed into a quick and inexpensive method of screening for 
cancer. Taking a small sera sample from an individual is much less 
expensive and intrusive than traditional screening methods such as 
mammograms. One early potential use for immunosignaturing would be to 
help follow at risk populations; such as those individuals with a family 
history of cancer. Immunosignatures could be taken at regular intervals 
between regularly scheduled mammograms. If the generated 
immunosignature from an interim test started to suggest a closer similarity 
to cancer, this could prompt physicians to follow the patient more closely 
or advise additional screening. Immunosignatures could be used in the 
same way for individuals who already have cancer. In this case, if an 
immunosignature suggested the person was developing an antibody 
signature indicative of a second tumor (or more closely loading on a latent 
factor biomarker), the individual could be followed more closely to detect 
the presence of a second primary tumor.  
 Screening for a specific disease state is fairly straightforward. A 
well curated collection of disease samples would form baseline control 
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factors. A sera sample would be taken from an individual and their sample 
would be allowed to freely load in a CFA model across relevant disease 
conditions. A significant loading on a disease factor would provide strong 
evidence for the person having a given disease.  
 There are a number of ways in which a presymptomatic screening 
test could be developed from immunosignatures. This could be done by 
collecting a longitudinal or time series sample of sera from an individual 
and following the factor loadings on a disease state over time. As the 
loadings on a disease factor tend to increase the individual could be 
watched more closely and additional screening for a disease could be 
recommended by a physician. A number of statistical methods and time 
series analyses such as latent transition analysis (LTA) could be 
employed to model this.  
Discussion: 
Immunosignaturing is a novel approach for understanding disease. 
A number of statistical methods including, exploratory factor analysis, 
confirmatory factor analysis, descriptive statistics, corrected t-tests, 
ANOVA, logistic and multinomial logistic regression, mixture models and 
structural equation modeling have shown promising abilities for analyzing 
different dimensions of immunosignatures. Immunosignaturing in the 
context of breast cancer has been shown to be a good platform for 
differentiating groups of samples based on disease status, determining the 
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disease status of specific samples as well as potentially serving a role in 
the discovery of antibodies for specific diseases. 
Despite many new challenges posed by immunosignaturing 
microarrays such as competitive binding and binding to multiple sites, the 
analyses conducted here clearly illustrate the usefulness of classical 
analytical methods to produce accurate results. The results are particularly 
noteworthy because of the lack of structure in the data and lack of a full 
pattern matched experimental design. The early results of structural 
equation modeling are very promising. Although wet lab validation is 
needed for the proposed methodology of antibody discovery, even if the 
latent factors turn out not to be a specific antibody, the model can still 
serve as an excellent biosignatures for disease screening.  
Early detection of cancer is among the best predictors of survival. 
Continued development of immunosignaturing into a screening and 
presymptomatic screening diagnostic tool will aid in early discovery and 
help turn the corner in the fight against cancer. Future research in this field 
should aim at validating the hypothesis that the latent factors modeled 
here are in fact antibodies and to develop the technology into a diagnostic 
screening tool. 
High Performance Computing: 
 In this study, each sample were loaded into a relational database. 
The database connectivity methods were used to access the data. With 
the multiple tests run, this eliminated the need to create a separate data 
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file every time a different format was needed for a different analysis. In 
addition to reducing the time needed to export data files and reimport 
them into SAS, this dramatically reduced storage space from extra files 
because the total data size for this experiment was over 10 gigabytes.  
 Multi-core and distributed grid processing was used to process the 
large number of pairwise comparisons. The syntax in chapter 2 on 
distributed grid processing was derived from the syntax used in this 
chapter. Also, multi-core processing was used to perform the Monte Carlo 
chapter used to decide on the use of the Satterthwaite T-Test presented in 
chapter 3 and used in this chapter.  
 High performance computing methods reduced storage and 
dramatically reduced the time necessary to process the large number of 
calculations necessary to test the more than 10,000 peptides present on 
the immunosignaturing array.  
Conclusion: 
 While simplistic methods can be a good starting point for modeling, 
methods such as the T-Test cannot fully unravel the complexity underlying 
the data when latent factors are present. Using structural equation 
modeling allows researchers the methods necessary to finally be able to 
ask questions not possible with simpler methods. Beyond being able to 
unravel complexity of latent factor not before possible, the use of the 
structural equation modeling framework may also prove useful for 
developing diagnostic devices to help screen for complex diseases.  
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CHAPTER 6 
CONCLUSION 
The living world we inhabit is massively complex. For years 
scientists lacked the data to ask many fundamental research questions in 
biomedicine. With the recent advances in computers, databases and new 
technologies such as microarrays we finally have access to the data 
necessary to investigate many areas of biomedicine including population 
health dynamics and the role genomics and proteomics play in disease. 
Unfortunately, now that we have the data, one major question is how to 
make sense of it amidst the complexity.  
Complexity is an inherent trait of the natural world we inhabit and in 
part a byproduct of sequential evolutionary change as well as from the 
enormous size and structure of modern biomedical data. New methods 
are necessary to help cope with the ever increasing size of biomedical 
data and to be able to effectively make sense of what the data means. 
However, before beginning to address the complexity in the natural world, 
new tools need to be made more accessible to average analysts to help 
cope with the volume of modern biomedical data.  
While it is imperative that researchers actually be able to physically 
process all of the data in a timely fashion, the result is not of high value 
unless the results obtained are accurate. Statistical methods are based on 
many assumptions and when violated they produce incorrect results; 
which are often not easily predictable in a precise fashion. Determining the 
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most appropriate model is difficult in the univariate case. The complexity 
added to the task is increased dramatically by the size and variability in 
modern biomedical data to the point that the question of interest is not 
simply which model makes the most sense but rather to which model 
performs the best across the entire range of the data. Monte Carlo 
Simulations combined with sampling methodologies are advocated as a 
way to test model performance and to pick the model which will provide 
the most accurate results across the spectrum of the dataset.  
Another added source of complexity in biomedical data is multi-
level or clustered structures in the data. Clustering in the data if left 
uncorrected can cause inaccurate results in the form of inflated type 1 
error rates. Additionally, there can also be disaggregated relationships in 
which ignoring clustering can produce parameter estimates not only with 
incorrect magnitudes but also incorrect signs. Unfortunately, despite the 
known hazards of not using multi-level modeling when clustering exists, 
the method is still underutilized in biomedicine. When multi-level modeling 
is used, it is not clear that it is used correctly and many critical pieces of 
information needed to accurately assess the models are omitted from 
journals.  
Beyond the limited use and arguably correct use of the method, 
multi-level models and experiments designed with them in mind are 
necessary to more fully understand the complexity in the data. For 
example, simply knowing that both physicians and patients have some 
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causal role in adherence to treatment is only of limited use. Understanding 
the interaction between the two and being able to know how much 
variance in adherence comes from physician and how much comes from 
patient factors is critical to being able to develop the most effective 
interventions possible. Failing to correct for clustering will give incorrect 
model results, but designing experiments to avoid clustering means the 
researcher is limiting the amount of information they are using and are 
ostensibly ignoring the inherent complexity of our natural world. The 
necessity of multi-level models is not simply to obtain correct parameter 
estimates but also to help us more fully understand and unravel the 
complexity amidst modern biomedical data. 
Finally, structural equation modeling is presented because the 
presence of latent factors makes an in depth analysis of modern 
biomedical data highly complex. Simpler classical methods are incapable 
of detecting or adequately modeling latent factors. Ignoring the presence 
of latent variables in biomedical data fails to explain the complex 
relationship among variables in the dataset. Method such as multi-level 
modeling and structural equation modeling are needed to unravel the 
complexity. In addition, confirmatory factor analysis or the measurement 
Future Directions 
The methods presented in this dissertation are highly useful, but do 
not constitute an exhaustive treatise on the analysis of biomedical data. 
Additionally, this dissertation focuses more on individual pieces rather 
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than how they can be integrated together into an enterprise workflow. As a 
result, a major future direction for this research is in integration of methods 
and methods into workflow. 
With respect to integration of methods, multi-level modeling and 
structural equation modeling can be integrated into a single model when 
necessary. The implementation of high performance computing in each 
chapter discusses how complexity of voluminous and computationally 
intense data often co-occurs with other complexities such as clustering or 
latent class variables. In the same context, clustering sometimes co-
occurs with latent class data. For example, assume that in the 
immunosignaturing study that the sera samples had come from different 
labs and that the expression was significantly different based on which lab 
the sample came from. Samples coming from participants from sets of 
families or diverse racial backgrounds may also lead to clustering in 
genomic the data due to the inherent genetic variability within the human 
population. These examples may all require the use of a multi-level model 
to correct for clustering. However, the need to use a multi-level model 
would not preclude researchers from also then investigating latent class 
variables. Studying the multi-level structure might produce potentially 
novel new information while still allowing for the investigation of latent 
factors.  
The methods are presented as individual chapters but are not 
entirely separate and unrelated to one another within the context of an 
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overall workflow for data analysis. More emphasis can be placed on 
integrating analysis into the workflow. Beyond the initial mention of 
integrating an analytic package such as SAS with a database, once the 
data is aggregated and loaded into a database or analytic program, 
automated processes could be written to perform a Monte Carlo 
simulation and select the most appropriate model. Then, the selected 
model based on a predefined target algorithm could be used to run a 
screening experiment on all of the samples in the dataset; in the same 
way the Satterthwaite T-Test was run on the peptides in the 
immunosignaturing study based on the Monte Carlo results. The results 
would then all be output into one aggregate report upon completion. The 
high performance computing method such as pipeline parallelism and 
multi-core processing could be integrated into this process.  
Providing tools to integrate the methods presented in this 
dissertation into a streamlined workflow is useful for a number of reasons. 
Providing simple automated tools will to help these methods to become a 
more normal part of standard research practices. This is because 
performing one task is less complex for the end researcher who may not 
have an informatics or statistics background. Providing a single validated 
package for researchers to use is also less error prone than having 
researchers perform many sequential manual tasks. Additionally, 
integrating and automating the process reduces time for an experiment to 
run.  
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However, beyond one experiment, having automated analytic 
processes and supporting methods (high performance computing) that 
can be widely applied to data within a given domain is a key part in 
building community wide informatics pipeline for integration and analysis 
of biomedical data. Such a system could be placed in the cloud to allow 
for real time and on demand processing and reporting of predefined data 
streams within biomedicine; thus removing the informatics burden from 
researchers such as epidemiologists, biochemists, geneticists in order to 
enable them to focus more directly on their core area of expertise.  
In the case of population health in which reports are received from 
multiple hospitals or labs where clustering is endemic to the data, multi-
level models could be directly integrated into the process flow. As data is 
received, it is loaded, normalized to a common data structure, variables 
denoting clustering are tagged during loading and normalization period 
which would be passed directly to a module performing multi-level 
modeling and finally the results of the model can be sent directly to the 
necessary recipient upon completion. Such results based on more 
accurate multi-level models would give a better reflection of differences 
between hospitals and labs or how covariates of interest are influencing 
spread of disease. 
Although the data is complex and the models presented in this 
dissertation are also complex, there are many common denominators. 
Specifically, there are many recurrent forms of complexity such as the 
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voluminous size of data, heterogeneous variances, clustering or latent 
constructs. By better understanding how and when they occur through 
concrete examples presented in this dissertation, we can use the methods 
presented to help address common complexity problems in a more 
automated process flow.   
Complexity from natural from natural and synthetic sources will 
continue to be a challenge for analyzing biomedical data. The 
advancement of the methods presented in this dissertation as well as 
integrating them more seamlessly into workflow and informatics pipelines 
will increase the pace of biomedical discovery. The driving goal behind 
this dissertation is that by advancing analytic methods and giving 
biomedical researchers tools to help facilitate analysis, the bench to 
bedside timeline can be decreased; ultimately ameliorating the quality of 
life four countless individuals.  
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